

# Index

## A

- Abraxane, 393, 417–418
- AC133+ progenitor cells (APC), 656
- Actium Cancer Treatment System, 452
- Activatable aptamer probe (AAP), 277
- Acute lymphoblastic leukemia (ALL)
  - chemotherapy, 782
  - molecular classification, 781
  - risk factors, 782
  - TPMT, 781
- Acute myeloid leukemia (AML)
  - cytarabine, 783
  - cytogenetics, 180
  - FLT3-ITD, 782
  - genzyme diagnostics, 181, 782
  - hematopoietic stem cells, 52
  - massively parallel DNA sequencing, 52
  - NGS analysis, 53
  - stem cell transplantation, 482
  - WT1 assay, 783
- Acute promyelocytic leukemia (APL), 53
- Adaptive phased-array thermotherapy, 632
- Adenomatous polyposis coli (APC), 311
- Adenoviruses (Ad)
  - GFP, 285–286
  - vectors
    - direct gene delivery, 511–512
    - intra-dermal delivery, 523
    - virus-mediated oncolysis, 538–540
- ADEPPT method, 65, 101
- Adipose tissue-derived biomarkers, 214
- AdnaGen's proprietary technology, 263–264
- Adoptive cell therapy (ACT)
  - antiangiogenic agents, 365
  - with antiangiogenic agents, 716
  - CTL, 715
  - EBV, 363
  - features, 362, 715
  - genetic engineering of, 717
  - gp100 and MART-1, 362
  - hybrid cell vaccination, 717–718
  - isolation, 714
  - NCI, 715
  - TILs, 362, 716
  - treating B-cell malignancies, 716–717
- Adoptive immunotherapy. *See* Adoptive cell therapy (ACT)
- Ado-trastuzumab emtansine, 388
- Advexin, 124
- Affibody molecules, 275–276, 645
- Affisomes, 451
- Afirma Gene Expression Classifier, 335–336
- Agilent SureSelect capture system, 36
- AI-850 porous particle, 414
- Albumin
  - drug carriers, 635
  - oligonucleotides, 415
  - paclitaxel formulation, 414–415
- Aldo-keto reductase family 1 B10 (AKR1B10), 175
- Allele-specific copy number analysis of tumors (ASCAT) profiles, 250
- Allele-specific inhibition (ASI), 560–561
- Allogeneic hematopoietic SCT (allo-HSCT), 364–365
- Alpha-(11)C-methyl-L-tryptophan (AMT), 683
- Alpha-fetoprotein receptor, 376
- Alpha-methylacyl-coenzyme A racemase (AMACR), 176, 219
- Ambion's RecoverAll™, 337
- AMN-107, 123
- Amplicon sequencing, 34–35
- Ampligen, 359
- Anaplastic lymphoma kinase (ALK), 69

- Aneuploidy, 3, 260, 679
- Angiogenesis  
 drug delivery systems, 657  
 EAls, 12  
 galectin-1, 13  
 VEGF, 13
- Annexin 3 (ANXA3), 217
- Antecedent genes. *See* Proto-oncogenes
- Antiangiogenic therapy  
 ACT, agents, 365  
 anticancer effects, 443–444  
 brivanib alaninate, 125  
 cell therapy, 497–498  
 circulating endothelial cells, 126  
 drug delivery systems, 657–658  
 imaging, 126–127  
 targeted gene therapy, 527–528  
 tumor endothelial markers, 127  
 VEGF-PET imaging, 128  
 VEGF signaling inhibitors, 127–128
- Antibody-cytokine fusion proteins, 372–374
- Antibody-dependent cellular cytotoxicity (ADCC), 381
- Antibody-directed enzyme prodrug therapy (ADEPT), 377–378
- Antibody-drug conjugates (ADC) technology  
 ado-trastuzumab emtansine, 388  
 brentuximab vedotin, 388–390  
 clinical trials, 389  
 pyrrolbenzodiazepines, 388  
 uses, 387
- Anticancer drugs  
 cancer biomarker, 133–134  
 categories, 17  
 nanoconjugates, 412
- Anti-CD55 antibody. *See* Viragen
- Antigen-specific cancer vaccines  
 MHC class I/II, 349–350  
 T helper lymphocytes, 349, 350
- Anti-HER2 antibody, 449
- Anti-oncogenes. *See* Tumor suppressor gene therapy
- Antisense oligonucleotides (ASO), 415, 430
- Anti-Thomsen-Friedenreich antigen (anti-TF-Ag) MAb, 374–375
- Apoptosis  
 autophagy, 11  
 Bcl-2, 10  
 caspase-mediated, 11  
 CTLs, 9  
 cytochrome c, 9–10  
 cytokines, 11  
 inhibitors, 9  
 nanodots, 400  
 NF- $\kappa$ B, 11  
 suicide program, 9
- Applied Biosystems®, 279
- Aptamers, 95, 276–278
- AQUA™, 176
- Arcturus CellPix II Laser Capture  
 Microdissection, 68
- ArcturusXT™, 279
- Aromatase inhibitors (AIs), 167
- ARvitamab (ARH460-23), 707
- Asparagine synthetase (ASNS), 687–688
- AT13148, 613
- ATM pathway, 27
- ATR pathway, 27
- Attractin, 138
- AuroLase™, 450–451
- Autoantibody biomarkers  
 estrogen receptor negative, 145  
 NAPPA, 147
- Autoantibody signatures, 96
- Autoimmune biomarkers  
 ECPKA, 102  
 PKA, 102  
 SEREX and SERPA, 101
- Automated digital microscopy (ADM), 118–119
- Autophagy, 11
- Averaged differential expression (ADE), 221
- B**
- Bacterial vector, targeted gene therapy, 529
- Baculoviral inhibitor. *See* Survivin
- Bavituximab, 375
- B-cell lymphomas  
 Bcl-2, 10  
 BCL6, 787  
 brentuximab vedotin, 788  
 genetic aberrations, 786–787  
 sequencing and microarray analyses, 787  
 vaccine, for follicular lymphoma, 788
- BCL2L12, 56
- BEAMing technology, 269–270
- Bevacizumab, 529
- BFAST, 39
- B7-H3, 214–216
- Biochips  
 circulating tumor cell detection, 270  
 molecular diagnosis  
 applications, 280  
 automated analysis, 281  
 DNA microarray, 281–282  
 FHIT gene, 282
- Biogen Idec's Rituxan®, 375

- Biomarker response ratio (BRR), 155
  - bioMérieux, 217
  - Biosensor, 398
  - BioServe, 171
  - BiovaxID™, 352, 714
  - Bispecific antibodies, 382
  - biSphere™, 624–625
  - Bladder cancer
    - FGFR3 mutations, 134
    - FISH assay, 134
    - NMP22 BladderChek, 135
    - urinary telomerase, 135
  - Blood DCs, 358
  - Bmi-1 oncoprotein, 200
  - Bombesin (BBN) peptides, 459
  - Bone marrow mononuclear cells (BMMNCs), 79
  - Bone tumor
    - cytogenetics, 144
    - diagnosis, 145
    - Ewing's tumors, 144–145
  - Boron neutron capture therapy (BNCT)
    - dendrimers, 438–439
    - liposomes, 631
    - nanotechnology, 445–446
  - Bortezomib, 486
  - Bostwick Laboratories, 217
  - BRACAnalysis, 295
  - BrachySil™, 443
  - Brachytherapy, 19, 443
  - BRAF mutation, 232
  - BRAF V600E, 54
  - Brain tumors
    - aptamers, 739
    - biomarkers
      - CD133, 137
      - circulating microvesicles, 137–138
      - EGFR inhibitors, 137
      - types, 136
      - 14-3-3zeta positive expression, 136
    - chemotherapy
      - CSC, 747
      - EGFR inhibitors, 746
      - gene promoter methylation testing, 745–746
      - individualization, 746
      - MDxHealth, 746
    - companion diagnostic, for viral gene therapy, 739–740
    - drug resistance, in GBM, 740
    - GAPVAC, 742
    - genetics and genomics of
      - CGH, 741
      - chromosome 1, 740
      - EGFR mutations, 741
      - FABP7, 740
      - MGMT, 741
      - NF- $\kappa$ B, 742
      - STAT3, 741
    - germ cell, 750
    - medulloblastoma, 749–750
    - meningiomas, 750–751
    - molecular diagnosis
      - advantages, 292
      - DNA microarray, 291–292
      - genetic alterations, 290
      - glioblastoma multiforme, 290–291
      - limitations, 292
      - medulloblastoma, 292
      - microvesicles, 291
      - neuroimaging, 291–292
      - numerical abnormalities, 289
      - structural alterations, 289
    - molecular diagnostics
      - combined neuroimaging, 744
      - diffusion MRI, 744
      - DNA microarray analysis, 744
      - epigenetic biomarkers, of GBM, 744–745
      - fDM, 744
      - gliomas, 743
      - MGMT, 745
      - multivariate analysis, 745
      - predictor, of outcome in GBM, 745
      - proteomics of, 744
    - neuroblastoma, 748–749
    - OT, 747–748
    - prognosis, of glioblastoma multiforme, 743
    - proteomics
      - DESI-MS, 74
      - malignant glial tumors, 72–73
      - meningiomas, 73–74
      - NAPPA, 76
      - proteomic and genomic data, 76–77
    - sequencing
      - gliomas, 43–44
      - medulloblastoma, 44–45
    - supratentorial hemispheric diffuse
      - low-grade gliomas, 747
    - treatment, 739
- BRCA1 and BRCA2, 163, 293–294, 299–300
- Breast cancer
  - AZD2281, 752
  - biological finding, 772
  - biomarkers
    - autoantibody biomarkers, 145, 147
    - in breath, 147
    - carbonic anhydrase IX, 151

Breast cancer (*cont.*)

- Cdk6, 150
- centromere protein-F, 151
- chemotherapy, 166–167
- circulating tumor DNA, 148
- COX-2, 152
- diagnostic tests, 163–164
- ductal carcinoma in situ, 161
- efficacy of chemoprevention, 166
- flow cytometry for quantification, 148–149
- glycomic biomarkers, 152–153
- GP88, 152
- HER-2/neu oncoprotein, 153–154
- HMG A2, 154–155
- hypermethylated genes, 155
- lincRNAs, 156
- lipocalin 2, 155–156
- mammaglobin, 156
- miRNA biomarkers, 156–157
- in nipple aspiration fluid, 148
- PCNA, 159
- p27 expression, 157–158
- plasma proteomics, 149
- podocalyxin, 158
- prognostic role, 164–165
- progranulin, 158–159
- protein biomarkers, prevention, 165–166
- protein kinase C epsilon, 159
- RB gene, 159–160
- RCP, 160
- real time qPCR assay, 149–150
- SDRP, 161–162
- serum CA 15-3, 161
- tumor microenvironment, 162
- type III TGF- $\beta$  receptor, 162–163
- types, 145, 146
- BRCA1 and BRCA2 genes, 293–294
- cancer stem cells, 500–501
- chemotherapy
  - with AGTR1 antagonists, 759–760
  - antiestrogen drugs, 758–759
  - decreased breast density, 760
  - estrogen receptor mRNA, 760–761
  - 18F-FDG PET, 758
  - genomic predictors, 758
  - intrinsic subtypes, 761
  - NQO1 enzyme, 760
  - PEPI score, 760
  - p63/p73 pathway, 759
  - prediction of resistance, 762–763
  - response to paclitaxel, 758
  - retinoblastoma tumor suppressor gene, 758–759
  - subtyping, 761–762
  - trastuzumab treatment, 757
- circulating nucleic acid biomarkers, 294
- clinical and mammographic evaluation, 293
- conventional predictors, 753–754
- deCODE genetics, 294
- drug developing, 751–752
- EMSY gene, 293–294
- genomic profiles, 300–301
- HER2/neu-derived peptide vaccine, 756
- HER-2/neu oncoprotein, 99
- Her2 testing, 754–755
- impact, 772
- Insight<sup>®</sup> Dx profile, 767–768
- mammaprint test, 764–765
- MetaStat<sup>™</sup> test, 768
- molecular diagnostic tests, 296–297, 756
  - BRACAnalysis, 295
  - chemoprevention, 301
  - chemotherapy, 306
  - ER mRNA measurement, 306–307
  - ethical issues, 298–299
  - FAST, 305
  - ForeCYTE breast health test, 298
  - gene expression profiles, 298, 304–305
  - genetic biomarkers, 295, 298
  - HER2 gene, 301–302
  - IHC method, 302
  - intrinsic subtypes, 306
  - molecular imaging, 305–306
  - multiplex ligation-dependent probe amplification, 303
  - NewGene's assay, 295
  - oral contraceptive, 301
  - PAM50 gene signature test, 305
  - PET, 306
  - qualitative real-time PCR assays, 302–303
  - SPOT-Light<sup>®</sup> HER2 CISH kit, 303
  - staging, 298
  - tamoxifen, 306–307
  - Veridex, 304
- mouse ESC-based assays, 299–300
- mouse mammary cancer model, 773–774
- multigene expression prognostic constellation, 767
- novel protein expression, 772
- Oncotype DX<sup>™</sup> assay, 764
- pharmacogenetics of, 756
- PI3K pathway, 752
- primary, 772
- prognosis and response, 751
- prognostic gene biomarkers, 766–767
- prognostic marker assays, 765–766

- prognostic tests, 765
    - CHDH, 307
    - DACH1, 308
    - exagen's, 307
    - HOXB13:IL17BR, 307
    - Insight® Dx Breast Cancer Profile, 308–309
    - MapQuant Dx™ Genomic Grade™, 308
    - multigene expression prognostic constellation, 308
    - TaqMan noncoding RNA assays, 309
  - proteomic-based management, 757
  - proteomics
    - HER2 gene, 75
    - LCM, 74
    - mammary ductal cells, 74
    - nipple aspirate fluid, 75
    - protein biomarkers, 75
  - racial factors management, 768–769
  - RATHER consortium, 769
  - rational drug design, 752
  - sequencing
    - BRCA mutations, 45–46
    - CNA, 46
    - metastases, 47–48
    - miRNA, 47
    - TNBC, 48–49
    - whole-genome sequencing, 49
  - subtypes, 770–771
  - tailor local treatment, 763–764
  - TAILORx, 769–770
  - tamoxifen therapy, for ER-positive, 770
  - TaqMan noncoding RNA assays, 768
  - TargetPrint®, 764
  - TOP2A FISH pharmDx test, 765
  - triple-negative, 752
  - types, 772–773
  - WGS, 771
  - Brentuximab vedotin, 388–390, 788
  - BRIT1 gene
    - HMEC, 27
    - pathways, 27, 545
  - Brivanib alaninate, 125
  - Bruton's tyrosine kinase (BTK), 784
  - Bub 1 gene, 28
- C**
- CA 19-9, 213
  - CA-125, 206
  - Camposomes™, 406
  - CAMPTOSAR®, 406
  - Canavaninosuccinate, 186
  - Cancer antigens, 353
  - Cancer biomarkers. *See also specific biomarkers*
    - applications of
      - antiangiogenic therapy, 125–128
      - assessing efficacy, 124–125
      - drug resistance, 130–132
      - for early detection, 120
      - methylated DNA sequences, 120–122
      - miRNAs, 122
      - monitoring cancer therapy, 128, 130
      - MUC4, 122
      - peptide-based agents, 123–124
      - phase I clinical trials, 133–134
      - prognosis in cancer treatment, 128–129
      - proteomic biomarkers, 120
      - radiation therapy, 132
      - safety biomarkers, 133
    - categories, 87
    - challenges, 236
    - characteristics, 88
    - detection
      - CTCs, 118–119
      - DNA methylation, 108–114
      - epitomics, early detection, 108
      - kallikrein gene family, 118
      - metabolomic biomarkers, 104–108
      - nanobiotechnology, 114
      - with normal tissues, 115
      - proteomic technologies, 93–104  
(*see also* Proteomic technologies, cancer biomarkers)
      - ultrasound radiation, 115
      - in vivo* imaging, 116–118
    - organ/type
      - bladder cancer, 134–135
      - bone tumors, 144–145
      - brain tumor, 135–143
      - breast cancer, 145–167
      - cervical cancer, 168–169
      - gastrointestinal cancer, 169–177
      - HNSCC, 178–179
      - leukemia, 179–184
      - liver cancer, 185–186
      - lung cancer, 187–196
      - lymphoma, 184–185
      - melanoma, 197–199
      - MPM, 196–197
      - NPC, 199–201
      - oral cancer, 201–202
      - ovarian cancer, 202–208
      - pancreatic cancer, 209–214
      - prostate cancer, 214–229
      - renal cancer, 229–232
      - thyroid cancer, 232–234
    - ovarian cancer, 327–328

- Cancer biomarkers. *See also specific biomarkers (cont.)*
- prostate-specific antigen, 87
  - single vs. multiple biomarkers
    - gene expression, 88
    - MS profiling, 89
    - peptidome, 89
  - TNM, 87
  - types of
    - ccf-DNA, 91
    - CTCs, 91
    - epigenetic gene silencing, 89–91
    - HER3, 92
    - immunological biomarkers, 92
    - metastatic, 92
    - tumor microvesicles/exosomes, 93
    - validation and development, 234–235
- Cancer Genome Anatomy Project (CGAP), 30
- Cancer immunotherapy
- CEA, 350–351
  - characteristics, 369
  - chemoimmunotherapy, 368
  - consortium, 369
  - cytokines
    - definition, 347
    - interleukins and cancer, 348–349
    - natural adjuvants, 347
  - dendritic cells
    - clinical efficacy, 360–361
    - exosomes, 359
    - genetically modified, 358
    - limitations, 359–360
    - preclinical and clinical studies, 358–359
    - targeted protein vaccines, 356–357
    - telomerase mRNA, 356
    - tumor cell fusion, 357
  - lymphocytes
    - ACT, 361–363
    - antiangiogenic agents, 365
    - CD8+ T cells, 366–367
    - chimeric antigen receptor T cells, 363–365
    - CTLs, 365
    - hybrid cell vaccination, 367–368
    - T helper cells, 366
    - TILs, 367
  - multiple tumor-associated peptides, 351
  - tumor cell-based vaccines
    - active immunotherapy, 355
    - BioVaxID, 352
    - cancer antigens, 353
    - dinitrophenyl, 353
    - gene-modified, 353–355
    - OncoVAX, 352–353
    - vaccines
      - antigen-specific, 349–350
      - carbohydrate-based, 351
      - development, 349
- Cancer stem cells (CSCs)
- agents, 725
  - CD133, 137
  - pancreatic cancer, 210
  - proteomics, role of, 71
- Cancer therapeutics
- adoptive immunotherapy, 584–585
  - antisense oligonucleotides target, 584
  - DiLA2, 587
  - inhibition therapy, 585–586
  - oncomiRs, 584
  - restore levels, 585–586
  - tumor suppressor, 585
- Cancer vaccines
- antigen-specific, 349–350
  - carbohydrate-based, 351
  - characteristics, 369
  - DCs (*see* Dendritic cells (DCs))
  - development, 349
- Canine parvovirus (CPV), 419
- Cape Bushwillow, 661
- Carbohydrate-based cancer vaccines, 351
- Carbonic anhydrase IX (CA IX)
- in breast cancer, 151
  - RCC, 231
- Carbon magnetic nanoparticles (CMNPs), 419–420
- Carbon nanotubes (CNT), 420
- Carcinoembryonic antigen (CEA), 350–351
- Caretakers genes, 24–25
- Caspase-independent apoptosis, 11
- Castration-resistant prostate cancer (CRPC), 58
- CCI-781, 808
- CD133, 137
- CDH13, 227
- CD8+ T cells, 366–367
- CEACAM6, 165
- Celera. *See* Multigene expression prognostic constellation
- CellCarta™(Caprion), 65
- Cell cycle, 2
- Cell Genesys, 354
- CellSearch system, 270
- CellSelect, 498
- Cell therapy
- antiangiogenesis therapy, 497–498
  - cancer stem cells
    - breast cancer, 500–501
    - endothelial progenitor cells, 501
    - integrative nuclear signaling, 499

- in leukemia, 503
    - markers, 499–500
    - metastases, 501
    - in ovarian cancer, 503–504
    - therapeutic implications, 501–502
  - cell-mediated delivery, 474–475
  - CellSelect, 498
  - cytokine-induced killer cells, 496–497
    - description, 473
  - ESC vaccine, 492–493
  - genetic modifications
    - HSCs, 493
    - mesenchymal progenitor cells, 494–495
    - MSCs, 493–494
    - neural stem cells, 495
    - oncolytic adenoviruses, 494–495
  - hESC-derived NK cells, 492
  - HSCs (*see* Hematopoietic stem cells (HSCs))
  - immortalized cells, 496
  - immunization strategies, 504
  - immunotherapy
    - ex vivo* mobilization, 475
    - granulocytes, 475–476
    - humoral and cellular immunity, 475
    - monoclonal antibodies, 476
  - mesenchymal stem cells, 489–490
  - microencapsulated cells, 497–498
  - nanomagnets, 497
  - natural killer cells, 496
  - nonablative allogeneic HSC
    - transplantation, 490–491
  - stem cell transplantation (*see* Stem cell transplantation)
  - technologies, 474
  - UCB transplantation, 491–492
- CellTracks®, 119
- CellTracks® AutoPrep® system, 270–271
- Cell-type classifier, 564–565
- Cellular systems biology (CSB™), 699
- Center for Prostate Disease Research (CPDR), 217
- Centromere protein-F (CENP-F), 151
- Cerasomes, 406
- c-erbB-2. *See* HER-2/neu oncogene
- Cervical cancer
  - chromosomal instability, 168
  - exfoliated cervical cells, 169
  - HPV test, 168
  - hTERT, 169
- CFI-400945, 644
- Chemically programmed antibodies (cpAbs), 379
- Chemoembolization, 624, 625
- ChemoFX assay, 775–776
- Chemoimmunotherapy, 368
- Chemokines, gene therapy, 524–525
- Chemoradiation, tumor targeted drug delivery, 431
- ChemoRad NP, 431
- Chimeric antigen receptors (CARs)
  - ALL, 364
  - allo-HSCT, 365
  - minimal residual disease, 364
  - 19z1, 363, 533, 716
- Chimeric polypeptides (CPs), 416–417
- Choline, 140
- Choline phospholipid biomarkers, 105
- Chromogenic in situ hybridization (CISH), 303
- Chromogranin A (CGA), 189
- Chromosomal instability (CIN)
  - cervical cancer, 168
  - molecular diagnosis, 260
  - mutation, 4
  - p53, 3
- Chromosome translocations
  - hematological malignancies, 317
  - in leukemias
    - mixed lineage leukemia, 179
    - Philadelphia chromosome, 179
    - rearrangements, 180
- Chromothripsis, 39–40
- Chronic lymphocytic leukemia (CLL)
  - biomarkers
    - findings, 182
    - miRNAs, 183
    - risk factor, 183
  - BTK, 784
  - chromothripsis, 40
  - elimination of, 783
  - subgroups, 784
- Chronic myeloid leukemia (CML)
  - biomarkers
    - HAAH, 183–184
    - miRNAs, 183
  - sequencing, 54–55
- Chronic myelomonocytic leukemia (CMML), 53–54
- Chronic myeloproliferative diseases (CMPDs), 320–321
- Chronic neutrophilic leukemia (CNL), 54–55
- Circulating cell-free DNA (ccf-DNA), 91
- Circulating microvesicles, 137–138
- Circulating nucleic acids (CNAs), 46, 148, 294
- Circulating nucleosomes, 96–97

- Circulating tumor cells (CTCs)
- cancer biomarkers
    - applications, 91
    - automated digital microscopy, 118
    - CellTracks<sup>®</sup>, 119
    - circulating endothelial cells, 119
    - FAST, 118
    - lung cancer, 192
  - detection
    - BEAMing technology, 269–270
    - biochips/microfluidics, 270
    - CellTracks<sup>®</sup> AutoPrep<sup>®</sup> system, 270–271
    - ClearCell<sup>®</sup> FX System, 271
    - CTCscope system, 271
    - fiber-optic array scanning technology, 272
    - IsoFlux System, 272
    - lab-on-chip platform, 272–273
    - MagSweeper, 273
    - nano-Velcro, 273–274
    - plasma DNA, 269
    - refinements of, 274
  - nanooncology, 394–395
- Circulating tumor DNA, 148
- Cisplatin, 413
- Classification and Regression Tree (CART) analysis, 195
- Classification of Ovarian Cancer (CLOVAR), 775
- ClearCell<sup>®</sup> FX System, 271
- Clivatuzumab, 381–382
- Co-amplification at lower denaturation temperature-PCR (COLD-PCR), 261
- COLARIS AP<sup>®</sup>, 311
- COLARIS<sup>®</sup>, 313
- Cologuard<sup>™</sup>, 313
- ColonSentry, 173, 314
- Colony-stimulating factor 3 (CSF3R), 54
- Colopath<sup>®</sup>/ColorectAlert<sup>™</sup>, 315
- Colorectal cancer (CRC)
  - adenomatous polyposis coli, 311
  - blood samples, 314
  - cause, 790
  - chemotherapy, 791
  - circulating tumor cell biomarkers, 172
  - circulating tumor cells, 312
  - Colopath<sup>®</sup>/ColorectAlert<sup>™</sup>, 315
  - ColoVantage CRC test, 311
  - detection of, 311–312
  - diagnostic biomarkers, 174–175
  - DNA examination, 313–314
  - DNA microarray analysis, 792
  - drug resistance and response, 793, 795–796
  - EGFR blockade, 796–797
  - epigenetic mechanism, 792–793
  - growth factor receptors, 791
  - guanylyl cyclase C, 314–315
  - HNPCC, 174, 312–313, 790
  - innate drug resistance, 130
  - management, 177
  - minimally invasive screening and monitoring test, 315
  - miRNA biomarkers, 173
  - NCI, 790–791
  - OncoTrack, 793–794
  - panitumumab, 792
  - prevention and management, 175–176
  - proteomics, 77
  - resistance, 177
  - sequencing, 794–795
    - ERBB2, 50
    - microsatellite instability, 49
    - SOLiD/Illumina sequencing, 50
  - serum biomarkers, 171–172
  - survival, 176
  - treatment, 793
  - urinary biomarkers, 172–173
- ColoVantage CRC test, 311, 314
- Combretastatin, 428
- Combretum cafferum*, 661
- Comparative genomic hybridization (CGH), 258–259
- Complex human cancer genomes, 40–41
- Complex prostate-specific antigen (cPSA), 224
- Computer tomography (CT)
  - cancer biomarkers, 116
  - conventional investigations, 253
  - nanotechnology-based cancer therapy, 453–454
- Convection-enhanced delivery (CED), 442–443
- Cornell dots (C dots), 452–453
- Cotara, 381
- C-reactive protein (CRP), 189
- CRLX101, 433
- CTChip<sup>®</sup> FR System, 271
- CTCscope system, 271
- CUB domain-containing protein 1 (CDCP1), 92
- Curcumin, 407
- Cutaneous T-cell lymphoma (CTCL), 185
- Cyclic AMP-dependent protein kinase (PKA), 102
- Cyclin-dependent kinase-6 (cdk6), 150



- Cyclooxygenase-2 (COX-2), 152  
 Cycloset™ system, 421  
 CYFRA 21-1, 190  
 Cytarabine, 783  
 Cytochrome c (CC)  
   Apaf-1, 9  
   ATP, 9  
   chemotherapy drugs, 10  
 Cytokine gene therapy  
   ability, 516–517  
   GM-CSF, 520  
   IFN-g gene transfer, 519  
   IL-2, 517  
   IL-7, 518  
   IL-12, 518  
   IL-13, 518  
   IL-21 and IL-23, 519  
   mda-7/IL-24, 519  
   role of, 517  
   TGF- $\beta$  insensitive immune cells, 519–520  
 Cytokine-induced killer (CIK) cells  
   cell therapy, 496–497  
   virus-mediated oncolysis, 537  
 Cytokines  
   apoptosis, 11  
   monoclonal antibodies, 384  
 Cytolytic peptide melittin, 426  
 Cytotoxic T lymphocytes (CTLs)  
   apoptosis, 9  
   cancer immunotherapy, 365–366
- D**
- Dachshund (DACH1), 164  
 DC Bead™, 624  
 DC-derived exosomes (Dex), 359  
 DCVax vaccine, 712–713  
 DEC-205 antigen, 356  
 Defibrotide, 488  
 Dendrimers  
   boron neutron capture therapy, 438–439  
   dendronized polymers, 438  
   doxorubicin, 438  
   nanotechnology-based cancer therapy, 458–459  
   photodynamic therapy, 439–440  
   poly-L-lysine, 440–441  
   synthetic vector system, 440  
   uses, 437, 438  
 Dendritic cells (DCs)  
   cancer immunotherapy  
     CD34+ precursors, 356  
     clinical efficacy, 360–361  
     exosomes, 359  
     genetically modified, 357–358  
     limitations, 359–360  
     preclinical and clinical studies, 358–359  
     targeted protein vaccines, 356–357  
     telomerase mRNA, 356  
     tumor cell fusion, 357  
   vaccines  
     anticancer effect, 714  
     BiovaxID™, 714  
     DCVax, 712–713  
     ex vivo loading, 712  
     fusion, of tumor cells, 714  
     gene therapy techniques, 713  
     *imetelstat*, 713  
     lentivirus vectors, 713–714  
 Deoxycytidine kinase (DCK), 698  
 Des-gamma-carboxy prothrombin (DCP), 185  
 Desmin, 175  
 Desorption electrospray ionization (DESI)  
   brain tumors, 74  
   cancer biomarkers, 96  
   for cancer diagnosis, 66–67  
 Dexosomes, 408  
 2D gel electrophoresis (GE)  
   ADEPPT method, 65  
   CRC, 77  
   esophageal cancer, 78  
   leukemia, 79  
   meningiomas, 73  
   p53, 70  
   prostate cancer, 80  
   serological proteome analysis, 96  
 Diatom peptide vector (DPV) technology, 664  
 Dicycloplatin (DCP), 649  
 Digital karyotyping, 259–260  
 Digital transcript subtraction (DTS)  
   method, 252  
 Dihydrofolate reductase gene (DHFR), 29  
 Dihydropyrimidine dehydrogenase (DPD), 730–731  
 Dinitrophenyl (DNP), 353, 711  
 Diphtheria toxoid (DT), 351  
 Disease-associated balanced chromosome rearrangements (DBCRs), 37  
 DK-MICROBE, 252–253  
 3D MRS imaging, 141  
 DNA double-strand breaks (DSBs), 4  
 DNA microarray analysis  
   biochips, 281–282  
   brain tumors, 291–292  
   GBM, 142  
   receptor protein tyrosine phosphatase  $\beta$ , 143  
 Doxil, 393

- Doxorubicin
  - dendrimers, 438
  - DNCs, 412
  - oncoproteomics, 83
- 2D Polyacrylamide gel electrophoresis (2D-PAGE)
  - cancer biomarkers, 93–94
  - proteomic technologies, 275
- Drug delivery systems
  - Affibody<sup>®</sup> molecules, 645
  - albumin-based, 635
  - angiogenesis, 657
  - antiangiogenesis strategies
    - endothelial cells, 658
    - methods, 657–658
  - anticancer drugs, 405
  - antisense oligonucleotides, 415
  - approaches, 644
  - cell-based drug delivery
    - APC, 656
    - cell-mediated, 655
    - mononuclear phagocytes, 655–656
    - RBC, 656
  - cerasomes, 406
  - cisplatin, 413
  - classification, 404
  - computational approach, 667
  - DCP, 649
  - dendrimers (*see* Dendrimers)
  - diagnosis and treatment
    - PRIT, 636
    - radioactive iodine, 636–637
    - SST, 636
  - doxorubicin nanocarriers, 412
  - exosomes, 408
  - folate-based, 653–655
  - folate-linked nanoparticles, 408
  - genetic strategy, 646
  - glutathione *S*-transferase, 650
  - HIFU, 653
  - hydrogel nanoparticles, 407
  - IGDD, 667
  - implants for systemic delivery, 656–657
  - influx and retention, 648–649
  - innovative methods
    - bacterial ghosts, 622
    - live bacterial vectors, 621–622
    - methods, 618
    - microparticles, 622–625
    - polyamine conjugate, 621
    - with polymeric drugs, 618–621
    - taxane, 621
  - iron oxide nanoparticles, 409
  - lipid-based nanocarriers, 409
  - liposomes, 405–406
    - advantages, 629
    - antibody-targeted, 630
    - boron containing, 631
    - DepoFoam technology, 631
    - doxorubicin, 632
    - folate-PEG, 633
    - hyperthermia and liposomal, 631–632
    - non-PEGylated liposomal
      - doxorubicin, 633
    - nucleic acid complexes, 632–633
    - Stealth<sup>®</sup> technology, 630
    - ultrasound-mediated anticancer drug release from, 634
- micelles
  - CPT, 410–411
  - Medicelle<sup>™</sup> delivery system, 410
  - paclitaxel micelle, 410
  - three stealth systems, 411
  - uses, 409, 410
- minicells, 411
- multiple processes, 617
- nanoconjugates, 412
- nanomaterials, 412–413
- nanomedicines, 442
- novel transporters to photosensitizers, 646–647
- paclitaxel formulation
  - AI-850, 414
  - albumin, 414–415
  - cremophor/ethanol, 413
  - gold nanoparticles, 414
- PDT, 647–648
- PEG technology
  - Enzon, 626–627
  - intron, 627–628
  - Nektar PEGylation, 627
- pegylated nanoliposomal formulation, 415–416
- peptide-linked nanoparticle delivery, 416
  - with peptides, 651
- pharmacosomes features, 634–635
- poly-2-hydroxyethyl methacrylate nanoparticles, 416
- polymeric nanoparticles, 407
- polypeptide–doxorubicin-conjugated nanoparticles, 416–417
- proteins and peptides therapy
  - CELLECTRA<sup>™</sup> electroporation device, 663
  - DPV technology, 664
  - Emisphere's Eligen<sup>™</sup> system, 664
  - modification of, 665
  - peptide-based agents, 665–666

- peptide–cytokine complexes, 666
  - problems, 663
  - with radionuclides, 666
  - ProtoSphere nanoparticle technology, 417–418
  - radionuclides, 648
  - ReCODE™ technology, 650–651
  - RNA nanotechnology
    - pRNA, 441
    - siRNAs, 442
  - routes of, 618
  - SCA technology, 628
  - strategies
    - antineoplastic drug implants, 639
    - direct injection, 637–639
    - electrochemotherapy, 641
    - intra-arterial injection, 640
    - pressure-induced filtration, 641
    - selective destruction, 642–644
    - in situ* production, 642
    - TNT, 639–640
  - Targaceutical® technology, 645–646
  - targeted delivery (*see* Tumor targeted drug delivery)
  - TfR, 651
  - therapeutic agents, 644
  - tumor-activated prodrug therapy, 649
  - ultrasound and microbubbles treatment, 652–653
  - vascular-targeting agents
    - alpha-emitting antibodies, 659
    - angiolytic therapy, 659–660
    - vs.* antiangiogenesis agents, 662
    - blood-transporting vessel, 658–659
    - cadherin inhibitors, 661
    - fosbretabulin tromethamine, 661–662
    - phosphatidylserine, 660
    - vadimezan, 660–661
  - vesicular systems, 628–629
  - vitamin B12 oral, 653–655
  - zinc oxide, 418
- Drug discovery methods and development
- anticancer biotherapeutics classification, 591, 592
  - biochips/microarrays
    - applications, 599
    - definition, 598
    - impact, 598
    - laboratories-on-a-chip, 600
    - RPMA, 599–600
    - USC, 598–599
  - biomarkers applications
    - (*see also* Cancer biomarkers)
    - DCE-MRI uses, 596
    - expression, of molecular target, 593
    - molecular imaging, 594–595
    - phase I clinical trials, 597–598
    - plucked hair, 596–597
    - RECIST, 594
    - signaling pathways, 593
    - thymidylate synthase, 595
    - VEGF-PET, 596
  - biotechnology, 591, 592
  - ICT, 613
  - multiple pathway, 613
  - nanobiotechnology application
    - cellular level drug design, 611
    - challenges, 609
    - dendrimers, 610–611
    - futures, 612
    - PNA, 609–610
    - poly-L-lysine, 611
  - proteomic application
    - ARIAD Pharmaceuticals, 606
    - Bcr–Abl kinase inhibitor imatinib, 604
    - functional screen, of proteases, 605
    - intracellular protein kinases, 605
    - intracellular signaling pathways, 605
  - RNAi application
    - advantages of, 608–609
    - basis of, 606
    - identification, of genes, 606–607
    - siRNAs focus, 607–608
    - validation of, 608
  - sequencing application, 612
  - stem cells application
    - advantages and limitations, 602–603
    - ESCs, 602
    - HTS, 601–602
    - screen anticancer drugs, 604
    - target identification, 601
    - therapeutic effects, 600–601
  - Ductal carcinoma in situ (DCIS), 161
  - DX-2240 MAB, 376
  - Dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI), 126–127, 596
- E**
- Electrochemotherapy, 530–531, 641
  - Electrogene, 530–531
  - Electroporation, 512–513
  - ELTD1, 138–139
  - Embryonic stem cells (ESCs), 71, 579–580
  - EMSY, 164, 293–294
  - Endogenous inhibitors of angiogenesis (EAI)s, 12

- Endogenous peptides, 65  
 Endothelial progenitor cells (EPCs), 501  
 Enhanced permeability and retention (EPR) effect, 619  
 Enzon, 626–627  
 Epigenetic gene silencing  
   aberrant CpG island methylation, 90  
   colorectal cancer, 90  
   DNA methylation, 89  
 Epigenomics Inc., 174  
 Epigenomics marker machine, 112  
 Epithelial aggregate separation and isolation (EASI), 274  
 Epithelial/epidermal growth factor receptor (EGFR)  
   gefitinib, 131  
   HNSCC, 178  
   inhibitors, 694  
     DxS test kit, 191  
     FISH analysis, 190  
     gefitinib, 190  
   PKB/Akt, 137  
   targeted gene therapy, 531  
 Epithelial membrane protein-1 (EMP-1), 131  
 Epithelial–mesenchymal transition (EMT), 155–156, 500  
 Epitomics, 108  
 Epstein–Barr virus (EBV), 363  
 ERCC1–XPF expression, 124  
 Esophageal cancer  
   biomarkers  
     Barrett’s esophagus, 169  
     hypermethylation, 169  
     miRNA expression profile, 170  
   proteomics, 78  
 eTag assay system  
   applications, 97  
   EGFR, 98  
   Monogram Biosciences, 98  
 Ewing’s sarcoma family tumors (ESFTs), 144  
 Excision repair cross-complementing 1 (ERCC1), 190  
 Exfoliated cervical cells, 169  
 Exhaled breath condensate (EBC), 194  
 Exosomes  
   cancer biomarkers, 93  
   dendritic cells, 359  
   dexosomes, 408  
   sequencing, 35  
 Extracellular protein kinase A (ECPKA), 102  
*Ex vivo* mobilization, 475
- F**  
 FANCI–FANCD2, 4–5  
 Fanconi anemia, 4–5  
 FANG™ vaccine, 565, 710  
 Fas (Apo-1), 524  
 FAST, 305  
 Ferritarg, 381  
 Fiber-optic array scanning technology (FAST), 118, 272  
 Fibroblast growth factor receptor 3 (FGFR3), 134  
 Firestorms genomic profile, 300  
 Flat genomic profile, 300  
 Flow cytometric analysis  
   breast cancer, 148–149  
   leukemia, 317  
   molecular diagnosis, 256  
 FLT3-ITDs, 53  
 Fluorescent in situ hybridization (FISH), 258  
 Fluorodeoxyglucose (FDG)-PET, 682–684  
 5-Fluorouracil (5-FU), 474–475  
 Focal adhesion kinase (FAK), 754  
 Folate-linked nanoparticles, 408  
 ForeCYTE breast health test, 298  
 Formalin-fixed paraffin embedded (FFPE) tissues, 35  
 FoxM1, 28  
 FOXP3, 94  
 Fragile histidine triad (FHIT) gene, 282  
 FRAP1, 688  
 Free prostate-specific antigen (fPSA), 81, 224  
 Fullerenes, 422, 466  
 Functional diffusion map (fDM), 141
- G**  
 Galectin-1 (gal-1), 13  
 Gastric cancer  
   molecular diagnosis, 315  
   real-time RT-PCR, 171  
   SELDI-TOF MS, 170  
   TIMP-1, 170  
 Gastrointestinal cancer  
   biomarkers  
     CRC, 171–177  
     esophageal cancer, 169–170  
     gastric cancer, 170–171  
   CRC, 790–797  
   esophageal, 789  
   gastric, 790  
 Gata2 gene, 478  
 Gatekeepers genes, 24–25  
 Gefitinib, epithelial membrane protein-1, 131

- Gemtuzumab ozogamicin, 387
- Genasense®, 199
- Gene chip technology, leukemia, 318
- Gene-directed enzyme prodrug therapy (GDEPT), 525–526
- Gene expression profiling (GEP)
- applications, 677–678
  - breast cancer, 298, 304–305
  - classification, 675–676
  - DNA, 30
  - expression, 678
  - microarray analysis, 31, 676
  - molecular diagnosis
    - DNA tags, 266
    - gene signatures, 267
    - microarrays, 265
    - multiphoton laser-scanning microscope, 264
    - SAGE technology, 266
    - suppression subtractive hybridization, 267
    - tumor specimens, 265
  - OnkoMatch tumor genotyping, 678
  - predict chromosomal instability, 679
  - prostate cancer, 330
  - techniques, 31
- Gene-modified cancer cell vaccines
- cytokines, 354
  - GVAX, 354
  - K562/GM-CSF, 354–355
- GeneSearch™ breast sentinel lymph node intraoperative assay, 304
- Gene therapy
- apoptotic approach, 543–544
  - cell-based cancer gene therapy
    - classification, 514–515
    - human HSCs, 515–516
  - chemokines, 524–525
  - definition, 509
  - direct gene delivery
    - electroporation, 512–513
    - gene expression control, 513
    - hyperthermia, 514
    - injection into tumor, 511–512
    - nanoparticles, 514
    - radiation-guided gene therapy, 513–514
    - radioprotective gene therapy, 514
  - Fas (Apo-1), 524
  - gene-directed enzyme prodrug therapy, 525–526
  - genetic defects correction, 526–527
  - immunogene therapy (*see* Immunogene therapy)
  - immunosuppressive function, 525
  - monoclonal antibody, 523
  - nitric oxide-based cancer gene therapy, 545–546
  - with radiotherapy, 526
  - strategies for, 509–510
  - targeted gene therapy
    - antiangiogenic therapy, 527–528
    - bacterial vector, 529
    - cancer-specific gene expression, 529
    - cancer-specific transcription, 530
    - electrogene and electrochemotherapy, 530–531
    - epidermal growth factor-mediated DNA delivery, 531
    - gene-based targeted drug delivery, 531–532
    - hematopoietic stem cells, 534–535
    - hypoxic tumor cells, 532
    - nanomagnets, 535
    - nanoparticles, 535–536
    - receptor-mediated endocytosis, 536
    - retroviral particles hitchhiking, 530
    - stem cells, 534
    - T cells, 532–533
  - tumor suppressor gene therapy (*see* Tumor suppressor gene therapy)
  - virus-mediated oncolysis (*see* Virus-mediated oncolysis)
- Gentium SPA. *See* Defibrotide
- Genzyme. *See* Mozobil
- Germ cell brain tumors, 750
- GlaxoSmithKline, 708
- Glioblastoma multiforme (GBM), 290–292. *See also* Cancer biomarkers
- CD133, 137
  - methylation profiling, 139
  - microvesicles, 137–138
  - miRNAs, 141
  - multigene predictor, 142
- Glioma actively personalized vaccine consortium (GAPVAC), 742
- Gliomas
- MYBL1, 44
  - PLGGs, 43
- Global Cancer Genomics Consortium (GCGC), 813
- Globo H (GH), 351
- Glucose-regulated protein (GRP78), 83, 167
- Glycochenodeoxycholic acid, 186
- Glycoprotein biomarkers, 98–99, 152
- Glycosaminoglycan (GAG), 427
- G250MN, 231

- Gold conjugates, 116
- Gold nanoparticles (AuNP)  
with bombesin, 459  
cancer diagnosis, 396–397  
nanotechnology-based cancer therapy, 444  
paclitaxel formulation, 414  
radiation therapy, 446–447  
tumor targeted drug delivery  
Aurimune-T and AuriTax, 423  
chemical properties, 423  
electron affinity, 422–423  
epigallocatechin gallate, 424–425  
Raman scattering, 423–424  
T cells, 437  
TNF- $\alpha$ , 423  
transferrin, 424
- Gold nanorods, 397–398, 459–460
- Golgi protein-73 (GP73), 185
- GP88, 152
- Graft-*versus*-host disease (GVHD), stem cell transplantation, 485–486
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 520, 709
- Granulocytes, 475–476
- Green fluorescent protein (GFP), 31
- GRNVAC1, 356
- Guanylyl cyclase C (GCC), 174, 312, 314–315
- GVAX cancer vaccines, 354
- H**
- Hairy cell leukemia (HCL), 54, 318
- HC2 assay, cervical cancer, 309–310
- Head and neck squamous cell carcinoma (HNSCC)  
biomarkers, of HPV-related, 780  
HPV16, 178  
MMP1, 179  
molecular-targeted therapy, 779  
nanobiochip sensor technique, 316  
ProteinChip, 316–317  
PTTG, 178
- Heat shock protein (HSP), 805
- Hematological malignancies  
ALL, 781–782  
AML, 782–783  
CLL, 783–784  
JAK2 gene, 781  
MDS, 786  
MM, 784–786  
myeloproliferative disorders, 780  
sequencing  
AML, 52–53  
APL, 53  
CMML, 53–54  
CNL and atypical CML, 54–55  
HCL, 54  
MDSs, 51–52  
stem cell transplantation  
acute myeloid leukemia, 482  
lymphoma, 483  
multiple myeloma, 482–483  
myelodysplastic syndrome, 483
- Hematopoietic stem cells (HSCs)  
AML, 52  
cell-based cancer gene therapy, 515–516  
ERG, 478  
*ex vivo* model, 478–479  
features, 477  
genetic modifications, 493  
GM-CSF-secreting cell vaccines, 485  
green fluorescent protein, 478  
from hESCs, 480  
in immune system, 479  
long-term results, 483–484  
renal cell cancer, 485  
Scl-Gata2-Flil triad, 479  
targeted gene therapy, 534–535  
T-cell reconstitution, 484  
*in vitro* differentiation, 477  
zinc-finger repressor Gfi-1, 477–478
- Hepatic veno-occlusive disease (VOD), 487–488
- Hepatocellular carcinoma (HCC)  
glycoprotein biomarkers, 98  
proteomics, 78  
sequencing, 55
- HER3, cancer biomarkers, 92
- HerceptTest (DakoCytomation), 75
- Herceptin, 50
- Hereditary nonpolyposis colorectal cancer (HNPCC), 174, 312–313, 790
- HER2 gene, 301–302
- HER-2/neu oncogene, 687
- HER-2/neu oncoprotein  
FISH, 154  
mechanisms, 154  
patient, determination, 153
- Herpes simplex virus (HSV), 540
- Herringbone-chip (HB-Chip), 270
- HerScan™, 154
- High-affinity peptidomimetic ligand (LLP2A), 665
- High-intensity focused ultrasound (HIFU), 653
- High mobility group protein A2 (HMGA2), 154–155
- High resolution magic angle spinning (HR-MAS), 105

- High-throughput screening (HTS), 601–602
- Histone deacetylase (HDAC)  
 cancer biomarker, 113  
 mucins, 113–114
- Histone demethylases, 724
- Histone methyltransferases (HMT), 724
- Homeobox 13 (HOXB13), 164
- HOTAIR. *See* Long intervening noncoding RNAs (lincRNAs)
- hsa-miRNA-30c, 157
- HtrA1, ovarian cancer, 205
- huHMFG1, 380
- Human epidermal growth factor receptor-2 (HER2), 75, 754
- Human epididymis protein 4 (HE4), 205
- Human homolog of SDRP (hSDRP), 161
- Human mammary epithelial cells (HMECs), 27, 500
- Human papilloma virus (HPV)  
 cervical cancer, 309–310  
 sequencing, 51
- Human telomerase reverse transcriptase (hTERT), 135
- Human telomerase RNA (hTR), 135
- Human Tumor Gene Index, 30
- Humoral proteomics, 99–100
- Huntingtin interacting protein 1 (HIP1), 220, 330–331
- Hyaluronic acid (HA), 432
- Hybrid capture (HC) 2 assay, 168
- Hybrid cell vaccination, 367–368
- Hyperbaric oxygen (HBO)  
 radiotherapy, 643  
 selective destruction, of cancer, 703
- Hypermethylated DNA, prostate cancer, 218
- Hypermethylated genes, 155
- Hyperparathyroidism-jaw tumor (HPT-JT) syndrome, 212
- Hyperthermia  
 gene therapy, 514  
 thermal ablation, 449
- Hypoxia-inducible factor-1 (HIF-1), 105–106
- I**
- Ibritumomab tiuxetan, 380
- Id proteins, 67
- IFN- $\gamma$  gene transfer, 519
- IFN-related DNA damage resistance signature (IRDS), 763
- Illumina HiSeq™ 2000, 37
- IMA901, 351
- Image-guided drug delivery (IGDD), 667, 683
- Imatinib mesylate, 355
- Imetelstat vaccine, 713
- Immunobead RT-PCR, 264
- ImmunoCyt™/uCyt+™, 337
- Immunogene therapy  
 cancer cell vaccines, 520  
 cytokines (*see* Cytokine gene therapy)  
 dendritic cell vaccines, 520–521  
 nucleic acid-based cancer vaccines  
 DNA cancer vaccines, 521–522  
 RNA vaccines, 522  
 strategies, 516  
 viral vector-based cancer vaccines, 522–523
- Immunoliposomes, 383–384
- Infinium™, 259
- InPath System, 168
- Insight® Dx Breast Cancer Profile, 308–309
- Insulin-like growth factor-binding protein (IGFBP)-1, 176
- InSure®, 313
- Integrative nuclear FGFR1 signaling (INFS) pathway, 499
- Interaction Discovery Mapping™, 97
- Interleukin-2 (IL-2), 348, 517
- Interleukin-6 (IL-6), 348
- Interleukin-7 (IL-7), 518
- Interleukin-12 (IL-12), 348, 518
- Interleukin-13 (IL-13), 518
- Interleukin-15 (IL-15), 348
- Interleukin-21 (IL-21), 519
- Interleukin-23 (IL-23), 519
- Interleukin-24 (IL-24), 348–349
- Interleukin-17A (IL-17A), 348
- Interleukin-17B receptor (IL17BR), 164
- Internal tandem duplication (ITD) mutations  
 in FLT3 (FLT3-ITD), 782
- International Cancer Genome Consortium (ICGC), 42, 814–815
- Invasiveness gene signature (IGS), 685–686
- In vivo* imaging, cancer biomarkers  
 CT, 116  
 MRI, 117  
 optical systems, 116  
 PET, 117  
 xenon-enhanced MRI, 118
- In vivo* tumor illumination, 285–286
- Ion AmpliSeq™ Cancer Panel, 35
- Ion AmpliSeq™ Comprehensive Cancer Panel (CCP), 35
- Ion AmpliSeq Library Kit 2.0, 35
- Ion channels  
 transient receptor potential, 15  
 transport, 613  
 types, 15
- Iron oxide nanoparticles, 409

IsoFlux System, 272  
IT-101 (Calando), 421

## J

J591 antibody, 374

## K

Kallikrein gene family, 118, 222  
K562/GM-CSF, 354–355  
KW-2871, 380–381

## L

Lactate, 140

Laser capture microdissection (LCM)

- cancer tissue proteomics, 66
- 2D PAGE, 100
- prostate cancer, 331–332
  - alpha-1-antichymotrypsin, 222
  - PSA, 222
  - SELDI ProteinChip MS technology, 223
- proteomic technologies, 278–279
- uses, 68

Laser-induced cancer destruction

- CNTs, 447
- light-controlled delivery system, 448
- nanocarriers, 448
- photosensitizer molecules, 448–449
- plasmon-resonant gold nanorods, 447
- poly(lactic-co-glycolic acid)
  - nanoparticles, 448

Layered expression scanning (LES), 279

Lentivirus vectors, 358

Leukemia

- biomarkers
  - chromosome translocations, 179–180
  - CLL, 182–183
  - CML, 183–184
  - DNA methylation, 180
  - drug resistance, 184
  - gene mutations, 180–181
  - MDS, 184
  - molecular diagnostic techniques, 181
  - proteomic technologies, 182
- cancer stem cells, 503
- chromosome translocations, 317
- chronic myeloproliferative diseases, 320–321
- Fanconi anemia, 4–5
- flow cytometry, 317
- gene chip technology, 318
- hairy cell leukemia, 318

laboratory assessment, 318–319  
minimal residual disease, 320  
molecular probes, 319–320  
proteomics

- acute myeloid leukemia, 79
- biomarkers, 78
- 2D GE, 79

Li–Fraumeni syndrome, 27

LightCycler™, 302

Lipocalin 2 (Lcn2), 155–156

Liposomes, drug delivery systems

- advantages, 629
- antibody-targeted, 630
- boron containing, 631
- DepoFoam technology, 631
- doxorubicin, 632
- folate–PEG, 633
- hyperthermia and liposomal, 631–632
- non-PEGylated liposomal
  - doxorubicin, 633
- nucleic acid complexes, 632–633
- Stealth® technology, 630
- ultrasound-mediated anticancer drug
  - release from, 634

Liver cancer

- biomarkers
  - ALC1, 186
  - DCP, 185
  - GP7, 186
  - HCC, 186
  - serum AFP, 185
  - HCC, 797

Long intervening noncoding RNAs (lincRNAs), 156

Loss of heterozygosity (LOH), 259

Lung cancer

- biomarkers
  - autoantibodies, 187, 188
  - chemotherapy, 189–190
  - chronic inflammation, 189
  - CTCs, 192
  - DNA and RNA biomarkers, 195–196
  - EGFR inhibitors, 190–191
  - exhaled breath condensate, 194
  - gene expression profiling, 192–193
  - methylation profiling, 193
  - miRNA, 193–194
  - NSCLC, 187
  - in NSCLC, 189
  - SCLC, 187
  - serum protein biomarkers, 194–195
  - tNOX, 195
  - types, 188
  - VOCs, 196



- chemotherapy, 803
- classification system, 802
- crizotinib, 797–798
- EGFR inhibitors development, 800–801
- ESC vaccine, 492–493
- LAD molecular subtypes, 324–325
- metagenes, 323
- methylation, 322–323
- molecular subtyping, 801
- proteomics, 79–80
- respiratory papillomatosis, 802
- serum biomarkers, 323–324
- testing, for prognosis, 803–804
- treatment
  - DxS test, 800
  - EGFR mutations, 798, 799
  - laboratory studies, 798
  - radiographic responses, 799
  - TKI gefitinib, 798
  - tumor biopsies, 799
- VeriStrat test and PFS, 324
- Lymphocytes
  - ACT, 361–363
  - antiangiogenic agents, 365
  - CD8+ T cells, 366–367
  - chimeric antigen receptor T cells, 363–365
  - CTLs, 365–366
  - hybrid cell vaccination, 367–368
  - T helper cells, 366
  - TILs, 367
- Lymphoma
  - biomarkers, 184–185
  - stem cell transplantation, 483
- Lynch syndrome. *See* Hereditary nonpolyposis colorectal cancer (HNPCC)
- M**
- M2, 593
- M13, 101
- MAb 806, 385
- Magnetic resonance imaging (MRI)
  - brain tumor, 141
  - breast cancer, 305–306
  - choline phospholipid biomarkers, 105
  - conventional investigations, 253
  - DCE-MRI, 126–127
  - functional diffusion, 682
  - nanoparticle self-assembly detection, 283
  - nanotechnology-based cancer therapy, 453, 461–462
  - tumor oxygenation and microvascular permeability, 117
- MagSweeper, 273
- MALDI-TOF MS
  - cancer tissue proteomics, 66
  - CRC, 77
- Malignant astrocytoma, 138
- Malignant glial tumors
  - glioblastoma multiforme, 72
  - MALDI MS tissue profiling technology, 73
  - SELDI-TOF MS, 73
- Malignant melanoma
  - BRAF mutation, 805
  - drug-resistant, 805
  - effective therapies, 804
  - heat shock protein, 805
  - pharmacogenomic-based therapies, 804
  - treatment, 804
- Malignant pleural mesothelioma (MPM)
  - SELDI-TOF and MS, 196
  - SMRP, 197
- Mammaglobin, 156
- Manganese superoxide dismutase (MnSOD)
  - polymorphism, 166
- MAPK signaling pathway, 429–430
- MapQuant Dx™ Genomic Grade™, 308
- Mass spectrometry (MS)
  - anaplastic lymphoma kinase, 69
  - immunoprecipitation, 69
- Master genes, 3
- Matrix metalloproteinases (MMPs), 114, 174
- MCJ, 140
- mda-7/IL-24, 519
- MDA-MB-231, 36
- MDScan™ microarray technology, 111
- Measles viruses (MVs), 540–541
- Medicelle™ delivery system, 410
- Medullary thyroid carcinoma (MTC), 234
- Medulloblastoma
  - brain tumors, 292, 749–750
  - CNVs, 44
  - genes, 45
  - tetraploidy, 45
- MEK1C121S, 42
- Melacine melanoma vaccine, 352, 712
- Melanomas
  - biomarkers
    - classification, 197, 198
    - Genasense®, 199
    - Wnt-5A and B-raf, 197
    - YKL-40, 198
  - mechanisms, 325
  - sequencing, 55–56
- Membrane-type serine protease-1 (MT-SP1)
  - cancer biomarkers, 100
  - proteomic technologies, 279–280

- Meningiomas  
 brain tumors, 750–751  
 classification, 73  
 2D GE, 73  
 proteomic technologies, 73
- Mesenchymal progenitor cells (MPCs), 494–495
- Mesenchymal stem cells (MSCs)  
 cell therapy, 489–490  
 genetic modifications, 493–494
- Mesenchyme Forkhead 1 (FOXC2), 500
- Mesomark™, 197
- Mesoporous silica nanoparticles (MSNs),  
 425–426
- Metabolomic biomarkers  
 brain tumors, 140–141  
 choline phospholipid, 105  
 hypoxia-inducible factor-1, 105–106  
 magnetic resonance, 105  
 metabolic profiling, 106–107  
 PFAAs, 107  
 TCA cycle, 104  
 urinary metabolomic biomarkers, 107–108
- Metastases  
 cancer stem cells, 501  
 tumor targeted drug delivery, 431
- Metastatic breast cancer (MBC)  
 circulating tumor DNA, 148  
 hypermethylated genes, 155
- Metastatic cancer biomarkers, 92
- Meta-tetra(hydroxyphenyl)chlorin  
 (mTHPC), 407
- Methylated DNA (meDNA)  
 advantages, 108–109  
 characteristics, 121  
 epigenomics marker machine, 112  
 histone deacetylase, 113  
 in leukemia, 180  
 MDScan™, 111  
 methyl-BEAMing technology, 109  
 mucins, 113–114  
 PCR with bisulfite  
 MethylScreen®, 110  
 MethySYBR, 111  
 MSP, 110  
 novel methods, 111  
 Rubicon MethylPlex technology, 111–112  
 Sequenom's integrated genetic analysis, 113  
 standardization issues and  
 recommendations, 122  
 workshop, 121
- Methylation profiling  
 MCJ, 140  
 methylSNP, 139  
 MGMT, 140  
 TMS1/ASC, 139
- Methylation-specific PCR (MSP), 110
- Methyl-BEAMing technology, 109
- Methylguanine-DNA methyltransferase  
 (MGMT), 131, 140, 741
- MethylScreen®, 110
- MethylSNPs, 139
- MethySYBR, 111
- MF-DeltaAkt, 361
- Micelles  
 drug delivery  
 CPT, 410–411  
 Medicelle™ delivery system, 410  
 paclitaxel micelle, 410  
 three stealth systems, 411  
 uses, 409, 410  
 nanotechnology-based cancer therapy, 461
- Microarray analysis, 31, 265.  
*See also* Biochips
- Microfluidic techniques  
 circulating tumor cell detection, 270  
 dynamic cell proteomics, 72  
 indirect fluorescence labeling, 71  
 passing coated channeled cells, 71
- Micrometastases detection, 288
- Microparticles drug delivery system  
 chemoembolization, 625  
 drugs releases  
 bisphere, 624–625  
 microcapsules, 625  
 polymer conjugates, 623–624  
 subcutaneous injection, 622, 623  
 therapeutic delivery systems, 622, 623  
 tumor embolization  
 with drug-eluting beads, 624  
 with radioactive, 624
- MicroRNAs (miRNAs)  
 antagonization, 587  
 antisense oligonucleotides, 587  
 brain tumors, 141  
 breast cancer, 156–157  
 copy number alterations, 575–576  
 CRC, biomarkers  
 ColonSentry, 173  
 high microsatellite instability, 173  
 diagnosis, 122, 581–583  
 diagnostic value of, 582–583  
 ESC, 579–580  
 fragile sites, 575, 576  
 gastric cancer, 171  
 genomic alteration, 576  
 hairpin, 573  
 lung cancer  
 let-7, 193  
 Ras protein, 194  
 role, 194

- and metastases, 580–581
- molecular diagnosis, 257
- NCode™ microarray, 578–579
- NPC, 201
- oncomirs, 577–578
- p53, 579
- pancreatic cancer
  - hierarchical clustering, 211
  - miR-155, 212
  - qRT-PCR, 211
- posttranscriptional mechanisms, 576–577
- prognostic value of, 583
- prostate cancer, 224
- renal cancer, 230
- schematic pathway, 573–574
- sequencing, 47
- signature, 581–582
- vs. siRNAs, 574–575
- therapeutics, 583–587
- thyroid cancer, 233–234
- in viral oncogenesis, 579
- Minicells, drug delivery, 411
- Minimal residual disease (MRD), 320
- MIRACLE project, 272–273
- Mixed-chimerism bone marrow
  - transplantation (mini-BMT), 491
- MLH1, 131
- MN58b, 105
- Molecular biology
  - apoptosis
    - autophagy, 11
    - CTLs, 9
    - suicide program, 9
    - therapeutic implications, 9–10
  - detection and treatment, 19–21
  - DNA damage and repair
    - anticancer therapies, 5
    - mechanism, 4–5
    - random mutations, 5
  - epidemiology, 16, 17
  - epigenetics
    - chromatin, 6
    - DNA methylation, 7
    - role of, 6
  - genesis
    - aneuploidy, 3
    - cell cycle and growth, 1–2
    - CIN, 3–4
  - hallmarks, 7–8
  - invasion and metastases, 13–14
  - ion channels, 14–15
  - management
    - chemotherapy, 17–18
    - radiotherapy, 18–19
    - surgery, 19
  - metabolic changes, 7
  - microenvironment, 15–16
  - omics, role, 19
  - replication, 13
  - telomeres and cancer, 5–6
  - tumor angiogenesis, 12–13
  - tumor proliferation, 8
- Molecular diagnosis
  - antibody-based detection systems, 254
  - biochip/microarrays
    - applications, 280
    - automated analysis, 281
    - DNA microarray, 281–282
    - FHIT gene, 282
  - brain tumors (*see* Brain tumors)
  - breast cancer (*see* Breast cancer)
  - cervical cancer, 309–310
  - classification, 255
  - colorectal cancer (*see* Colorectal cancer (CRC))
  - combined immunological and nucleic acid tests
    - immunobead RT-PCR, 264
    - MAbs and RT-PCR, 263–264
  - conventional investigations, 253–254
  - copy number variations
    - ASCAT profiles, 250
    - homozygous deletions, 249
    - somatic copy number alterations, 250
  - CTC detection (*see* Circulating tumor cells (CTCs))
  - CUP origin, 288–289
  - epithelial aggregate separation and isolation, 274
  - flow cytometry, 256
  - fluorescent in situ hybridization, 258
  - gastric cancer, 315
  - gene expression profiles
    - DNA tags, 266
    - gene signatures, 267
    - microarrays, 265
    - multiphoton laser-scanning microscope, 264
    - SAGE technology, 266
    - suppression subtractive hybridization, 267
    - tumor specimens, 265
  - genetic analysis
    - chromosomal instability, 260
    - comparative genomic hybridization, 258–259
    - digital karyotyping, 259–260
    - gene expression profiles, 260
    - loss of heterozygosity, 259
  - genome analysis, 254, 255

- Molecular diagnosis (*cont.*)
- head and neck cancer, 315–316
    - nanobiochip sensor technique, 316
    - ProteinChip, 316–317
  - hematological malignancies (*see* Leukemia)
  - lung cancer
    - LAD molecular subtypes, 324–325
    - metagenes, 323
    - methylation, 322–323
    - NSCLC, 322–323
    - SCLC, 321–322
    - serum biomarkers, 323–324
    - VeriStrat test and PFS, 324
  - management of
    - anticancer drugs selection, 339–340
    - cancer therapies, 338–339
    - determination of, 339
    - integrated genome-wide analysis, 340–341
    - molecular classification, 339
    - risk assessment and prevention, 338
  - melanoma, 325
  - micrometastases detection, 288
  - microRNA expression profiles, 257
  - molecular fingerprinting, 257–258
  - molecular imaging
    - optical systems, 287–288
    - PET, 286
    - radiolabeled peptide-based targeting probes, 286
    - in vivo* tumor illumination, 285–286
  - monoclonal antibodies, 262–263
  - multiplexed single-cell analysis, 282
  - mutation detection, 256
  - nanobiotechnology
    - magnetic nanoparticle probes, 284
    - nanoparticle self-assembly detection, 283
    - nanosensors, 283
    - quantum dots, 284–285
  - NCI role, 341
  - ovarian cancer (*see* Ovarian cancer)
  - pancreatic cancer, 328–329
  - PCR techniques
    - COLD-PCR, 261
    - real-time PCR, 262
    - real-time qPCR, 261–262
    - uses, 260–261
  - profile expression, 256
  - prostate cancer (*see* Prostate cancer)
  - proteomic technologies, 254
    - activatable aptamer probe, 277
    - advantages, 274–275
    - Affibody molecules, 275–276
    - aptamers, 276–278
    - automated image analysis, 278
    - laser capture microdissection, 278–279
    - layered expression scanning, 279
    - membrane-type serine protease-1, 279–280
    - survivin, 280
    - tumor biomarkers, 275
  - recombinant antibodies, 263
  - susceptibility determination, 264
  - telomerase activity, 268–269
  - thyroid cancer
    - Afirma Gene Expression Classifier, 335–336
    - gene expression, 336
    - MEN2B, 336
    - miRNA expression profile, 336–337
  - urinary bladder cancer, 337
  - viruses
    - DNA tumor virus, 251
    - viral agents detection, 251–253
- Molecular fingerprinting, 257–258
- Molecular imaging
  - advantages, 684
  - FDG-PET/CT, 682–683
  - functional diffusion MRI scan, 682
  - IGDD, 683
  - targeted gallium corrole, 683–684
  - virtual biopsy, 684
  - in vivo* imaging, 681
- Monoclonal antibodies (MAbs)
  - actions and uses, 372, 374
  - advantages, 385
  - antibody-directed enzyme prodrug therapy, 377–378
  - antibody-drug conjugates
    - ado-trastuzumab emtansine, 388
    - brentuximab vedotin, 388–390
    - clinical trials, 389
    - pyrrolobenzodiazepines, 388
    - uses, 387
  - CARs, 364
  - chemically programmed antibodies, 379
  - cytotoxin payload delivery, 377
  - DCs, 359
  - gene therapy, 523
  - humanized MAbs, 372, 373
  - immune activation, 377
  - immunotherapy, 476
  - limitations, 386
  - molecular diagnosis, 262–263
  - mTCR technology, 386–387
  - murine MAbs, 371
  - Poteligeo test, 379

- radiolabeled antibodies
    - clivatuzumab, 381–382
    - cotara, 381
    - ferritarg, 381
    - huHMFG1, 380
    - ibritumomab tiuxetan, 380
    - KW-2871, 380–381
  - selectivity methods
    - bispecific antibodies, 382
    - cytokines, 384
    - huHMFG1–huDNase I, 384
    - immunoliposomes, 383–384
    - immunotoxins, 383
    - injections, 383
    - MT201, 385
    - trifunctional antibodies, 383
  - single-chain antibody-binding protein
    - technology, 386
  - targeted antibody-based cancer therapy
    - alpha-fetoprotein receptor, 376
    - antibody-cytokine fusion proteins, 372–374
    - with anti-CD55 antibody, 375–376
    - anti-Thomsen-Friedenreich antigen, 374–375
    - bavituximab, 375
    - J591 antibody, 374
    - tumor blood vessels, 376
    - volociximab, 376
  - Monoclonal T-cell receptor (mTCR)
    - technology, 386–387
  - Mononuclear DCs, 358
  - Mozobil, 481
  - MPG algorithm, 56
  - MR metabolomics, 105
  - MS-qFRET, 284–285
  - MT201 MAb, 384
  - Mucins
    - diagnostic biomarker, 122
    - methylated DNA, 113–114
    - MUC4, 122
  - Multidrug resistance (MDR), 82, 455–456
  - Multigene expression prognostic constellation, 308
  - Multiphoton laser-scanning microscope, 31
  - Multiple endocrine neoplasia type 2B (MEN2B), 233, 336
  - Multiple myeloma (MM)
    - bortezomib treatment, 785
    - genetic subtypes, 784
    - overwhelming genomic chaos, 785
    - pharmacogenomic study of, 784
    - signal genetics, 786
    - stem cell transplantation, 482–483
  - Multiple tumor-associated peptides (TUMAPs), 351
  - Multiplexed cancer gene mutation analysis, 36
  - Multiplexed fluorescence microscopy (MxIF)
    - method, 282
  - Multiplex ligation-dependent probe amplification (MLPA), 303
  - MutaQuant™, 321
  - MutaScreen™, 321
  - MVA-HPV-IL2 vaccine, 522
  - MYBL1, 43–44
  - Myelodysplastic syndromes (MDSs)
    - AML, 52
    - biomarkers, 184
    - Illumina GAIIX/HiSeq, 51
    - management, 786
    - stem cell transplantation, 483
  - Myriad's test, 333. *See also* BRACAnalysis
  - myT™Primer reagents, 262
  - MyVax® vaccine, 710
- N**
- nab™ technology. *See* ProtoSphere™ nanoparticle technology
  - N-acetylaspartate (NAA), 140
  - Nanobees, 426
  - Nanobiotechnology
    - nanowire, 114
    - NP-peptide complexes, 114
  - Nanobody-based cancer therapy, 445
  - Nanobombs, 457–458
  - Nanobubbles, 464
  - Nanodiamonds (NDs), 428–429
  - Nanodots, 400
  - Nanolaser spectroscopy, 400
  - Nanoliposomal CPT-11, 442–443
  - Nanomagnets
    - cell therapy, 497
    - targeted gene therapy, 535
  - Nanooncology
    - clinical applications, 466
    - convection-enhanced delivery, 442–443
    - definition, 393
    - nanobiotechnology
      - biosensor, 398
      - circulating cancer cells, 394–395
      - dendrimers, 394
      - drug delivery (*see* Drug delivery systems)
      - early detection of, 394
      - gold nanoparticles, 396–397
      - gold nanorods, 397–398
      - nanosensors, 395–396

- Nanooncology (*cont.*)  
 nanotubes (*see* Nanotubes)  
 nanowires, 403  
 prostate-specific antigen, 403  
 nanomedicine, 393
- Nanoparticles, targeted gene therapy, 535–536
- Nanorobotics, 464–465
- Nanoshell-based cancer therapy, 444–445
- Nanoshells, thermal ablation, 450–451
- Nanotechnology-based cancer therapy  
 anticancer effects  
 antiangiogenic therapy, 443–444  
 cytotoxic effects, 444  
 gold nanoparticles, 444  
 nanobody, 445  
 nanoshells, 444–445  
 devices, 442–443  
 diagnostic imaging  
 clinical trials, 455  
 computed tomography, 453–454  
 corneal dots, 452–453  
 magnetic resonance imaging, 453  
 nanosensor device, 454–455  
 sentinel lymph node mapping, 454  
 fullerenes, 466  
 MDR, 455–456  
 nanobombs, 457–458  
 nanoparticles, 456  
 nanorobotics, 464–465  
 physical agents  
 BNCT, 445–446  
 laser-induced cancer destruction,  
 447–449  
 radiation therapy, 446–447  
 thermal ablation (*see* thermal ablation)  
 ultrasound radiation, 452  
 TGF- $\beta$  inhibitors, 457  
 therapeutics combination  
 aptamer-conjugated magnetic  
 nanoparticles, 458  
 AuNP–BBN conjugate, 459  
 biomimetic particles, 458  
 dendrimers, 458–459  
 gold nanorods, 459–460  
 magnetic nanoparticles, 460  
 micelles, 461  
 MRI, 461–462  
 nanobialys, 461  
 nanobubbles, 464  
 PET imaging, 461  
 pHLIP nanotechnology, 462  
 photothermal therapy, 459–460  
 QD–aptamer–doxorubicin, 463  
 radiolabeled carbon nanotubes, 463–464  
 squalene-based nanocomposites, 463  
 targeted therapy, 462  
 thermal ablation, 461–462  
 ultrasound, 464
- Nanotubes  
 dual-mode imaging, 400–401  
 nanobiochip sensor technique, 399  
 nanodots, 400  
 nanolaser spectroscopy, 400  
 quantum dots, 402–403  
 single-molecule assays, 401–402  
 single-wall carbon nanotubes,  
 398–399
- Nano-Velcro technology, 273–274
- Nasopharyngeal carcinoma (NPC)  
 miRNA, 201  
 prevalence, 199  
 proteomic biomarkers, 199, 200
- Natural killer (NK) cells, 496
- Nektar PEGylation, 627
- Neural stem cells (NSCs), 495
- Neuroblastoma brain tumors, 748–749
- Neuroimaging biomarkers, DNA microarray  
 analysis, 142
- NewGene's assay, 46, 295
- NHERF-1, 158
- NHERF-2, 158
- Nipple aspirate fluid (NAF), 75, 148
- Nitric oxide-based cancer gene therapy  
 anticancer effects, 545–546  
 radiosensitization, 546
- NMP22 BladderChek, 135, 337
- Nonablative allogeneic stem cell  
 transplantation, 490–491
- Nonhomologous end joining (NHEJ), 4
- Non-small-cell lung cancer (NSCLC)  
 EGFR inhibitors, 190–191  
 platinum-based chemotherapy, 189  
 serum CGA and ProGRP, 189
- Nonsteroidal anti-inflammatory drugs  
 (NSAIDs), 152
- NOX Technologies Inc., 195
- Nuclear factor-kappaB (NF- $\kappa$ B), 11, 742
- Nucleic Acid Programmable Protein Arrays  
 (NAPPA), 75–79
- Nucleosomes, 697
- NuMA nuclear protein, 278
- O**
- Oligodendroglial tumors (OT)  
 chromosomal change, 748  
 clinical implementation, 748  
 LOH markers, 747–748

- O6-methylguanine methyltransferase (MGMT), 745
- Oncogenomics
  - anticancer treatments, 29
  - Bub 1 gene in cell division, 28
  - CGAP, 30
  - gene expression profiling, 30–31
  - Human Tumor Gene Index, 30
  - interaction of cancer genes, 29–30
  - oncogenes, 24
  - tumor suppressor genes
    - alleles, 24
    - BRIT1, 27
    - chromosomal location and function, 25, 26
    - gatekeepers and caretakers, 24–25
    - and metastases, 28
    - mutations, 24
    - p16, 25, 27
    - p53, 25
    - Rb, 27
- Oncolytic adenoviruses, 494–495
- OncoMap, 36
- Onco-miRNAs, 577
- OncomiRs
  - cluster of miRNAs, 577
  - dysregulation of miRNA expression, 577, 578
  - patterns of miRNA, 577
- Oncoproteomics
  - ADEPPT, 65
  - biomarkers, 63
  - cancer cell mitochondria, 70
  - cancer tissue proteomics, 66
  - CellCarta technology, 65
  - CSCs, 71
  - DESI, 66–67
  - drug resistance
    - chemotherapy, 82
    - glucose-regulated protein, 83
    - multidrug resistance, 82
  - Id proteins, 67
  - integrate genomics and proteomics, 72
  - LCM technology, 68–69
  - microfluidic techniques
    - dynamic cell proteomics, drug, 72
    - indirect fluorescence labeling, 71
    - passing coated channeled cells, 71
  - morphoproteomics, 64
  - MS for oncogenic chimeric proteins, 69
  - organ systems
    - brain tumors, 72–74
    - breast cancer, 74–77
    - CRC, 77
    - esophageal cancer, 78
    - HCC, 78
    - leukemia, 78–79
    - lung cancer, 79–80
    - pancreatic cancer, 80
    - prostate cancer, 80–81
    - phosphoproteomics, 67–68
    - p53 protein, 70–71
    - ProteinChip system, 70
    - proteomic-based profiling, 64
    - role of, 63
    - tumor immunology and invasiveness, 81–82
- OncoTrack, 177
- OncoVAX<sup>®</sup>, 352–353, 710–711
- Onyvax, 353
- Oral cancer
  - flexAnalysis and ClinProt bioinformatic software, 202
  - MALDI-TOF MS, 202
  - morbidity and mortality rates, 201
- Oropharyngeal squamous cell carcinomas (OPSCC), 780
- OvaRex<sup>®</sup> MAb, 377
- Ovarian cancer
  - advantages, 328
  - biomarkers, 327–328
  - diagnosis, 202
  - epitomics approach, 203–204
  - gene expression studies, 204–205
  - HE4 protein in urine, 205
  - HtrA1, 205
  - multiplex assays, 207–208
  - mutation of genes, 206
  - prevalence, 202
  - serum albumin-associated peptides and proteins, 207
  - serum biomarkers, 206
  - tests, 208
  - types, 203
  - cancer stem cells, 503–504
  - chemotherapy, 774–775
  - clinical diagnosis, 325–326
  - CLOVAR, 775
  - drug-resistant
    - ChemoFX assay, 775–776
    - HGSC, 776
    - LRP1B expression, 777
    - quantitative RT-PCR, 777
    - side population (SP) cell, 776
    - Yale apoptosis assay, 775–776
  - gene mutation, 326
  - genetic test, 326
  - immunoassays, 328
  - KRAS variant, 774

- Ovarian cancer (*cont.*)
- pathway-targeted therapies
    - CSCs, 778
    - equipments, 779
    - molecular aberrations, 779
    - platinum therapy, 778
    - rapamycin, 777
    - sequencing, 56–57
  - OvaSure, 207
  - OvPlex™, 208
  - 15O-water PET, 128
- P**
- Paclitaxel
- drug delivery
    - AI-850, 414
    - albumin, 414–415
    - cremophor/ethanol, 413
    - gold nanoparticles, 414
    - nanovehicles, 427
  - Paired-end sequencing
    - copy-neutral rearrangements, 37
    - DBCRs, 37
    - genome-wide paired-end sequencing, 38
    - HACE1, 38
  - PAM50 gene signature test, 305
  - Pancreatic cancer
    - biomarkers
      - cancer stem cells, 210
      - classification, 209
      - discovery and validation, 210
      - histone modification, 210–211
      - miRNA, 211–212
      - parathyroid cancer, 212
      - proteomic biomarkers, 212–214
      - survival rate, 209
    - histone modifications predict treatment response, 807
    - KRAS mutations, 329
    - proteomics, 80, 328–329
    - treatment, 806–807
    - types, 806
  - Pancreatic ductal adenocarcinoma (PDAC), 211
  - Panitumumab, 792
  - Papillary thyroid carcinoma (PTC), 232
  - Parathyroid carcinoma (PC), 212
  - PathVysion, 340
  - PCA3 gene, 216–217, 332–333
  - Pediatric low-grade gliomas (PLGGs), 43–44
  - PEG Intron, 627–628
  - Peptide-based agents, cancer biomarkers, 123–124
  - Peptide nucleic acid (PNA), 609–610
  - Perfluorocarbon (PFC) emulsion, 432–433
  - Personalized analysis of rearranged ends (PARE), 689–690
  - Personalized cancer therapy
    - biomarker impacts
      - GOLPH3, 688
      - HER-2/neu oncogene, 687
      - L-ASP, 687–688
      - predictive markers, 688
      - sequencing for discovering, 689–690
      - VeraTag™ assay system, 690
    - cancer prognosis
      - GEP, 685–686
      - IGS, 685–686
      - microarray analysis, 685
      - risk assessment, 686
    - cancer tissue proteomics, 725–726
    - COLTHERES consortium, 812
    - computational model role
      - kinetically tailored treatment, 731–732
      - mathematical model, 732
    - computer and imaging technology, 812–813
    - definition, 671
    - design
      - epigenetic enzymes, 724
      - gene therapy strategy, 723
      - SAGE, 723–724
      - stem cells, 724–725
    - development factors, 672
    - drug discovery challenges, 811
    - functional antibody-based, 705, 707
    - GCGC, 813
    - Genomic Cancer Care Alliance, 813
    - heterogeneity, 672
    - ICGC, 814–815
    - integrated genome-wide analysis, 813–814
    - integration of various technology, 673
    - metastasis, 738
    - molecular diagnostics
      - AmpliChip P53, 700
      - aptamers, 700–701
      - chromosomal alterations analysis, 675
      - classification using microarrays, 675–676
      - CTC detection, 679
      - CUP, 676–677
      - CYP450 activity modulation, 680
      - DNA repair biomarkers, 677
      - gene-level information into pathway-level information conversion, 680
      - GEP, 675–679
      - impact of, 674, 675
      - molecular imaging role, 681–684
      - monoclonal antibodies, 701



- oncogenic pathway signatures, 680–681
- RNA splicing analysis, 674
- unraveling the genetic code, 684–685
- molecular profiling, 701–702
- nanobiotechnology application, 723
- oncoproteomics application, 725
- organs
  - B-cell lymphomas, 786–788
  - brain tumor, 738–751
  - breast cancer, 751–774
  - gastrointestinal cancer, 789–797
  - head and neck cancer, 779–780
  - hematological malignancies, 780–786
  - hepatocellular carcinoma, 788–789
  - liver cancer, 797
  - lung cancer, 797–804
  - malignant melanoma, 804–806
  - ovarian cancer, 774–779
  - pancreatic cancer, 806–807
  - prostate cancer, 807–811
- pharmacogenetics of chemotherapy
  - CYP1A2, 729
  - cytotoxicity, 729
  - DPD, 730–731
  - irinotecan, 731
  - TPMT gene, 730
- pharmacogenomic-based chemotherapy
  - molecular characteristics, 727–728
  - testing microsatellite instability, 728
  - whole-genome technology, 727
- PREDICT consortium, 815
- predicting and monitoring response
  - biomarker-assays, 690–691
  - ChemoFx assay, 691
  - DCK, 698
  - ex vivo testing, 691–692
  - gemcitabine and cytosine arabinoside, 698
  - gene expression patterns, 692–693
  - genetic mutations, 694
  - genetic variations, 695
  - genomic analysis, 693
  - genotype-dependent efficacy, 693–694
  - nongenetic factors, 695
  - PET imaging with TKI, 699
  - protein analysis, 696
  - RDA™, 694
  - real-time apoptosis monitoring, 696–697
  - serum nucleosomes, as indicators, 697
  - targeted microbubbles, 697–698
  - TSB™, 699
- radiation therapy
  - genetic profiles, 722
  - novel approach, 719
  - screening blood, 719, 722
  - sensitivity biomarkers, 722–723
  - side effects, 719
- sequencing role, 726–727
- systems biology, 673–674
- target
  - ACT, 714–718
  - anticancer medicines, 705, 706
  - clinical trials, of vaccines, 719–721
  - glycoproteins, 704
  - peptide vaccines, 718
  - PI3K/AKT pathway, 704–705
  - selective destruction, 702–704
- vaccines
  - antigen-specific approach, 708–709
  - patient-specific cell-based, 712–714
  - tumor-derived vaccines, 709–712
- p27 expression
  - chemotherapy, 157–158
  - prostate cancer, 223
- p16 gene
  - cyclin D–CDK complexes, 25
  - germline mutations, 27
  - Li–Fraumeni syndrome, 27
- p53 gene
  - apoptosis, 25
  - cancer biomarker, 124–125
  - histones, 25
  - tumor suppressor gene therapy, 544–545
- P-glycoprotein (Pgp), 412, 456, 733, 734
- Phage display technology
  - ADEPPT, 101
  - applications, 100
  - M13, 101
- Philadelphia chromosome, 179, 317
- pHLIP nanotechnology, 462
- Phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway, 704–705
- Phosphatidylserine (PS), 375, 660
- PhosphoScan®, 67
- Photodynamic therapy (PDT), 439–440, 647–648
- Photothermal therapy, 459–460
- PI3K signaling pathway, 77, 123
- Pituitary tumor-transforming gene (PTTG), 178
- Plasma-free amino acids (PFAAs), 107
- Plasma proteomics, 149
- Plastin3 (PLS3), 172
- PLK4, 644, 704
- Podocalyxin, 158
- Poly(amidoamine) (PAMAM) dendrimers, 394
- Polyglutamate (PG), 619–620
- Poly-2-hydroxyethyl methacrylate nanoparticles, 416

- Poly-L-lysine (PLL)
  - dendrimers, 440–441
  - drug discovery, 611
- Polymeric drugs
  - diverse group, 618
  - EPR effect, 619
  - polyglutamate, 619–620
  - protein–polymer anticancer, 620–621
- Polymersomes, 434
- Poly(ethylene glycol) (PEG) technology
  - Enzon, 626–627
  - intron, 627–628
  - Nektar PEGylation, 627
- Positron emission tomography (PET)
  - breast cancer, 306
  - cancer biomarkers, 117
  - choline phospholipid biomarkers, 105
  - conventional investigations, 253
  - molecular diagnosis, 286
  - nanotechnology-based cancer therapy, 461
  - virus-mediated oncolysis, 537–538
- Poteligeo test, 379
- Potelligent® technology, 380
- Preoperative Endocrine Prognostic Index (PEPI Score), 760
- Pretargeted radioimmunotherapy (PRIT), 636
- Previstage™, 174, 315
- pRNA, 441, 557
- ProfileQuant®, 321
- Progastrin-releasing peptide (ProGRP), 189
- Progranulin biomarker, 158–159
- Progression-elevated gene-3 (PEG-3), 529, 538
- Prolaris test, 333
- Proliferating cell nuclear antigen (PCNA), 159
- Promyelocytes, 53
- Promyelocytic leukemia and the retinoic receptor- $\alpha$  (PML-RARA), 53
- Prophage vaccine, 711
- ProPSA (<sup>2</sup>proPSA), 225
- Prostasomes, 226
- Prostate cancer
  - biomarkers
    - B7-H3, 214–216
    - cancer genetics, 216
    - detection in urine, 216–217
    - epigenetic biomarkers, 218
    - exosomes, 219
    - gene expression analysis, 219
    - genetic biomarkers, 220
    - HIP1, 220
    - Id proteins expression, 220–221
    - integrative genomic and proteomic profiling, 221
    - kallikreins, 222
    - LCM for diagnosis, 222–223
    - microarray technology, 223
    - miRNA, 224
    - mRNA, 221
    - obesity, 214
    - phi, 226
    - p27 loss, 223
    - proPSA, 225
    - prostasomes, 226
    - prostatic intraepithelial neoplasia, 218
    - PSA, 225
    - PSMA, 226–227
    - sarcosine, 227
    - in semen, 224–225
    - serum protein fingerprinting, 227–228
    - silenced CDH13 gene, 227
    - tests, 228
    - types, 215
  - detection of, 809–810
  - diagnostics, for guiding therapy of, 808
  - ETS gene fusion, 57
  - exome sequencing, 58–59
  - gene expression analysis, 330
  - huntingtin interacting protein 1, 330–331
  - integrative genomics, 331
  - LCM, 331–332
  - lifestyle changes, 810
  - nanotechnology, 329–330
  - PCA3 gene detection, 332–333
  - PCTC, 809
  - peptide vaccine for, 810–811
  - PHI, 334
  - prolaris test, 333, 809
  - Prostate Core Mitomic Test™, 333–334
  - prostate-specific antigen, 329
  - prostatic intraepithelial neoplasia, 333
  - proteomics
    - 2D GE, 80
    - iPSA, 81
    - LCM, 81
    - profile, 331
    - PSA, 80
  - PTEN, 57
  - semen test, 335
  - SNP screening, 334
  - TMPRSS2–ERG, 58
- Prostate circulating tumor cells (PCTC), 809
- Prostate Core Mitomic Test™, 333–334
- Prostate Health Index (phi), 226
- Prostate-specific antigen (PSA)
  - cancer biomarkers, 87
  - prostate cancer, 80–81, 225
- Prostate-specific membrane antigen (PSMA), 226–227

- Prostatic intraepithelial neoplasia (PIN), 218, 333
- Protein biomarkers, 165–166
- ProteinChip Biomarker System (Vermillion), 97
- ProteinChip System (Bio-Rad), 70
- Protein kinase C epsilon (PKC epsilon), 159
- Protein Stabilized Liposome (PSL™), 406
- Proteomic technologies, cancer biomarkers cancer classification, 120
- antibody-based detection
  - antibody-based detection: BioForce Nanosciences Inc., 95
  - antibody-based detection: FOXP3, 94
  - antibody-based detection: PSA, 95
  - aptamer-based molecular probes, 95
  - autoimmune biomarkers
  - autoimmune biomarkers: ECPKA, 102
  - autoimmune biomarkers: PKA, 102
  - autoimmune biomarkers: SEREX and SERPA, 101
  - cancer cell mitochondria, 101
  - cancer immunomics, 96
  - circulating nucleosomes, 96–97
  - DESI, 96
  - 2D PAGE, 93–94
  - eTag assay system, 97–98
  - glycoprotein biomarkers, 98–99
  - HER-2/neu oncoprotein, 99
  - humoral proteomics, 99–100
  - LCM, 100
  - membrane-type serine protease-1, 100
  - phage display technology
  - phage display technology: ADEPPT, 101
  - phage display technology: applications, 100
  - phage display technology: M13, 101
  - ProteinChip technology, 97
  - role of, 93, 94
  - SELDI-TOF MS, 102
  - serum proteome analysis, 103
  - targeted MS, 103
  - tissue proteomics, 104
  - triple quadrupole MS, mutant proteins, 103
- DESI (*see* Desorption electrospray ionization (DESI))
- ProtoKinetix technology, 376
- Proto-oncogenes, 24
- ProtoSphere™ nanoparticle technology, 417–418
- Proxinium, 383
- Pseudomonas* exotoxin, 383
- PSP94, 225, 335
- Pyrosequencing™, 139
- Q**
- QIAGEN Marseille biochips, 281
- Qualitative real-time PCR (qRT-PCR) assays, 302–303
- Quantum dots (QDs)
- lymph node mapping, 454
  - nanobiotechnology, 284–285
  - nanotechnology-based cancer therapy, 463
  - nanotubes, 402–403
  - tumor targeted drug delivery, 435
- Quantum rods (QRs), 435
- R**
- R547 (Roche), 133, 597
- Radiation-guided gene therapy, 513–514
- Radiation therapy
- brachytherapy, 19
  - gene therapy combination, 526
  - genetic profiles, 722
  - novel approach, 719
  - role of, 18
  - screening blood, 719, 722
  - sensitivity biomarkers, 722–723
  - side effects, 719
- Radioprotective gene therapy, 514
- Ranpirnase, 562, 564
- Real-time PCR
- CRC, 174
  - DNA methylation, 218
  - leukemia, 181
  - molecular probes, 320
  - with myT™ Primer reagents, 218
- Real-time quantitative PCR (qPCR)
- benefits, 149
  - cancer diagnosis, 261–262
  - comparison, 150
  - ER-positive and negative, 150
- Real-time RT-PCR, 171
- RECAF®, 376
- Receptor protein tyrosine phosphataseβ (RPTPβ), 143
- Recombinant antibodies, molecular diagnosis, 263
- Removab®, 383
- Renal cell cancer (RCC)
- biomarkers
  - gene expression profile, 229
  - miRNA, 230
  - prevalence, 229
  - prognosis and therapy, 230–232
  - proteomics, 230
- CDCP1 expression, 92
- IMA901, 351

- Renal cell cancer (RCC) (*cont.*)  
 oncogenomics, 29  
 stem cell transplantation, 485
- Representational oligonucleotide microarray  
 analysis (ROMA), 300
- Retinoblastoma tumor suppressor (RB) gene  
 antiestrogen drugs, 758–759  
 biomarkers, 159–160  
 cancer genes, 27
- Retroviruses, 24, 93, 358, 521, 713
- Reverse-phase protein microarrays (RPMA),  
 599–600
- Rexomun<sup>®</sup>, 383
- Riboflavin carrier protein (RCP), 160
- RNA disruption assay<sup>™</sup> (RDA<sup>™</sup>), 694
- RNA interference (RNAi)  
 advantages, 569  
 classes, 549  
 clinical trials  
   human phase I, 568  
   improving efficacy, 568–569  
   therapeutics, 567  
 delivery of siRNA therapeutics  
   with aptamer–siRNA chimeras, 552  
   chitosan-coated nanoparticles, 557  
   drug issues, 558–559  
   genetically engineered bacteria, 554  
   immunoliposome-based delivery  
     complex, 555–556  
   indiscriminate drug distribution, 555  
   intracellular target, 552  
   lipoplexes, 553  
   LNP, 554  
   methods of, 550, 551  
   nanoparticles, 553  
   nanosized liposomes, 558  
   polymeric delivery systems, 556  
   RNA nanotechnology, 556–557  
   *in vivo* delivery, 550, 551  
   wrapsome, 555  
 internal machinery, 549  
 limitations and disadvantages, 569–570  
 opportunities and challenges of, 570–571  
 siRNAs, 549  
 therapeutic applications  
   allele-specific inhibition, 560–561  
   alternative splicing affects, 562  
   animal models, 559  
   drug resistance, 564  
   dynamic and exciting, 560  
   FANG vaccine, 565  
   oncogenes inhibition, 561–563  
   onconase, 562, 564  
   synthetic circuit, 564–565  
   vaccination aims, 565–566
- RNA nanotechnology  
 pRNA, 441  
 siRNAs, 442
- RNA-Seq, 38–39
- RON receptor, 213
- Rubicon MethylPlex technology, 111–112
- S**
- Sarcosine, 227
- Sawtooth genomic profile, 300
- Scavidin<sup>®</sup>, 531, 532
- SELDI ProteinChip MS technology, 223
- Selected reaction monitoring (SRM), 103
- Sentinel lymph node (SLN) mapping, 454
- Sentinel Principle<sup>™</sup>, 173, 314
- Sequencing technologies  
 organs/systems  
   brain tumors, 43–45  
   breast cancer, 45–49  
   colorectal cancer, 49–51  
   head and neck cancer, 51  
   hematological malignancies, 51–55  
   hepatocellular carcinoma, 55  
   melanoma, 55–56  
   ovarian cancer, 56–57  
   prostate cancer, 57–59
- PCR, 33
- structural variants, 34
- TCGA, 42–43
- tumor DNA  
 amplicon sequencing, 34–35  
 anticancer therapies, resistance, 41–42  
 chromothripsis, 39–40  
 complex human cancer genomes, 40–41  
 exosome sequencing, 35  
 multiplexed cancer gene mutation  
   analysis, 36  
 mutational processes, 35  
 NGS-based molecular profiling, FFPE  
   specimens, 36–37  
 paired-end sequencing, 37–38  
 RNA-Seq, 38–39  
 sequencing cancer cell lines, 39  
 sequencing single cells, 41
- WGS, 33
- Sequenom's integrated genetic analysis, 113
- Serial analysis of gene expression (SAGE)  
 technology, 266
- Serological proteome analysis (SERPA), 96
- Serum biomarkers  
 BioServe, 171  
 Phenomenome Discoveries Inc., 172  
 protein biomarkers, 194–195  
 SELDI-TOF MS, 171

- Serum protein fingerprinting  
 brain tumor biomarkers, 143  
 prostate cancer, 227–228
- Signal transducer and activator of transcription  
 3 (STAT3), 131–132
- Silicon, 443
- Simplex genomic profile, 300
- Single-chain antibody-binding (SCA)  
 technology, 386, 628
- Single-nucleotide variations (SNVs), 39
- Sipuleucel-T, 355, 708
- Small-cell lung cancer (SCLC), 187
- Small interfering RNAs (siRNAs)  
 BRIT1, 27  
 delivery of therapeutics  
 with aptamer–siRNA chimeras, 552  
 chitosan-coated nanoparticles, 557  
 drug issues, 558–559  
 genetically engineered bacteria, 554  
 immunoliposome-based delivery  
 complex, 555–556  
 indiscriminate drug distribution, 555  
 intracellular target, 552  
 lipoplexes, 553  
 LNP, 554  
 methods of, 550, 551  
 nanoparticles, 553  
 nanosized liposomes, 558  
 polymeric delivery systems, 556  
 RNA nanotechnology, 556–557  
*in vivo* delivery, 550, 551  
 wrapsome, 555  
 vs. miRNAs, 574–575  
 RNA nanotechnology, 442  
 tumor targeted drug delivery, 429
- SnaPshot™, 139
- Soluble mesothelin-related peptides  
 (SMRP), 197
- Somatostatin receptor subtypes (SSTs), 636
- Sphingolipids, 642–643
- SPOT-Light® HER2 CISH kit, 303
- Stable isotope-based dynamic metabolic  
 profiling (SIDMAP), 106
- Stealth® technology, 630
- Stem cell transplantation  
 acute myeloid leukemia, 482  
 complications  
 delayed immune reconstitution, 486  
 graft-*versus*-host disease, 485–486  
 hepatic veno-occlusive disease, 487–488  
 neurological complications, 487  
 PBSC transplantation, 488–489  
 safety of, 488  
 tumor cell contamination, 486–487  
 viral infections and relapse, 486
- GM-CSF-secreting cell vaccines, 485  
 long-term results, 483–484  
 lymphoma, 483  
 multiple myeloma, 482–483  
 myelodysplastic syndrome, 483  
 peripheral blood  
 allograft procedure, 482  
 autologous procedure, 482  
 BM transplants, 480–481  
 PBSC, 480–481  
 renal cell cancer, 485  
 targeted gene therapy, 534  
 T-cell reconstitution, 484
- Steroid receptor coactivator 3 (SRC), 754
- Stimuvax®, 358
- Sulfonated gallium(III) corroles, 683–684
- SuperFluids™ technology, 405–406
- Suppression subtractive hybridization  
 (SSH), 267
- Suppressor of dextex protein (SDRP), 161–162
- Surface-enhanced laser desorption ionization  
 time-of-flight (SELDI-TOF) MS  
 breast cancer, 75  
 CRC, 77  
 CSF, 138  
 gastric cancer, 170  
 malignant glial tumors, 73  
 nasopharyngeal cancer, 199–200  
 ProteinChip technology, 97  
 proteomic technologies, 275  
 serum prostate-specific membrane  
 antigen, 102  
 serum protein biomarkers, 195  
 serum protein fingerprinting, 143
- Survivin, 10, 280
- ## T
- Tamoxifen  
 breast cancer, 49, 166–167  
 ER mRNA, 306–307  
 RB gene, 160
- TaqMan noncoding RNA assays, 309
- TaqMan®, 233, 337
- Taxol®, 422
- Taxosomes™, 406
- T cells, targeted gene therapy, 532–533
- TELCYTA™, 650
- Telomerase reverse transcriptase (hTERT), 356
- Telomeres, 5–6
- Telomeric repeat amplification protocol  
 (TRAP) assay, 268, 269
- Telomeric repeat elongation (TRE) assay, 268
- The Cancer Genome Atlas (TCGA), 42–43
- T helper cells, 349–350, 366

- Thermal ablation  
 Actium Cancer Treatment System, 452  
 affisomes, 451  
 AMF bursts, 450  
 Anti-HER2 antibody, 449  
 AuroLase™, 450–451  
 hyperthermia, 449  
 magnetic thermal ablation, 449  
 nanoshells, 450–451  
 targeted nanotherapeutics system, 449–450
- Thiopurine methyltransferase (TPMT) gene, 730
- Thomsen-Friedenreich antigen (TF-Ag) MAb, 374–375
- Thyroid cancer  
 Afirma Gene Expression Classifier, 335–336  
 biomarkers  
   biochemical features, 234  
   BRAF mutation, 232  
   gene expression, 232–233  
   MEN2B, 233  
   miRNA, 233–234  
 gene expression, 336  
 MEN2B, 336  
 miRNA expression profile, 336–337
- Tirapazamine (TPZ), 532
- Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), 170
- Tissue proteomics, 66, 104, 725–726
- Tissue systems biolig (TSB™), 699
- Topoisomerase, 736, 748
- Transferrin receptor (TfR), 651
- Transformation-induced oxidative stress, 643
- Transforming growth factor  $\beta$  (TGF- $\beta$ )  
 immunogene therapy, 519–520  
 immunosuppressive function, 525
- Trifunctional antibodies, 383
- TriGrid electrode array system, 513
- Triple-negative breast cancer (TNBC), 48–49
- Tumor-associated NOX (tNOX), 195
- Tumor cell-based vaccines  
 active immunotherapy, 355  
 BiovaxID, 352  
 cancer antigens, 353  
 dinitrophenyl, 353  
 gene-modified, 353–355  
 Melacine, 352  
 OncoVAX, 352–353
- Tumor-derived vaccines  
 DNP, 711  
 FANG™ vaccine, 710  
 GM-CSF, 709  
 mass spectrometry, 709  
 melacine melanoma, 712  
 MyVax®, 710  
 OncoVAX®, 710–711  
 prophage, 711
- Tumor DNA  
 amplicon sequencing, 34–35  
 anticancer therapies, 41–42  
 chromothripsis, 39–40  
 complex human cancer genomes, 40–41  
 exosome sequencing, 35  
 multiplexed cancer gene mutation analysis, 36  
 mutational processes, 35  
 NGS-based molecular profiling, FFPE specimens, 36–37  
 paired-end sequencing, 37–38  
 RNA-Seq, 38–39  
 sequencing cancer cell lines, 39  
 sequencing single cells, 41
- Tumor endothelial markers (TEMs), 127
- Tumor infiltrating lymphocytes (TILs)  
 ACT, 363  
 immunological biomarkers, 92  
 NeoR, 367  
 ScFv-y genes, 367
- Tumor microvesicles, 93
- Tumor necrosis therapy (TNT), 639–640
- Tumor Sequencing Project (TSP), 42
- Tumor suppressor gene therapy  
 BRIT1 gene therapy, 545  
 oncogenomics  
   alleles, 24  
   BRIT1, 27  
   chromosomal location and function, 25, 26  
   gatekeepers and caretakers, 24–25  
   and metastases, 28  
   mutations, 24  
   p16, 25, 27  
   p53, 25  
   Rb, 27  
   p53 gene therapy, 544–545  
 protooncogenes, 544
- Tumor targeted drug delivery  
 advantages, 419  
 anticancer agents, 432  
 antisense therapy, 430  
 canine parvovirus, 419  
 carbon magnetic nanoparticles, 419–420  
 carbon nanotubes, 420  
 C32/DT-A, 430–431  
 chemoradiation, 431  
 CycloSert™ system, 421  
 cytolytic peptide melittin, 426  
 DNA aptamer–micelle, 421–422  
 fullerenes, 422

- gold nanoparticles
    - Aurimmune-T and AuriTax, 423
    - chemical properties, 423
    - electron affinity, 422–423
    - epigallocatechin gallate, 424–425
    - Raman scattering, 423–424
    - TNF- $\alpha$ , 423
    - transferrin, 424
  - hyaluronic acid, 432
  - lymphatic system, 436
  - magnetic nanocrystals, 435–436
  - magnetic nanoparticles, 425
  - MAPK signaling pathway, 429–430
  - mesoporous silica nanoparticles, 425–426
  - metastases, 431
  - nanobees, 426
  - nanobody-shell polymeric micelles, 426–427
  - nanocell, 428
  - nanodiamonds, 428–429
  - nanoinmunoliposome-based system, 429
  - nanoparticle–aptamer bioconjugates, 436–437
  - nanovehicles, 427
  - perfluorocarbon emulsion, 432–433
  - polymer nanoparticles, 433–434
  - polymersomes, 434
  - principles, 418
  - quantum dots and rods, 435
  - siRNA, 429
  - T cells, 437
- Tyrosine kinase inhibitors (TKIs), 128, 699, 798
- Tyrosine kinases, 67–68
- U**
- Ultrasound, nanotechnology-based cancer therapy, 464
- Umbilical cord blood (UCB) transplantation, 491–492
- Urinary biomarkers, 172–173
- Urinary bladder cancer, 337
- Urinary metabolomic biomarkers, 107–108
- UroVysion™, 337
- V**
- Vaccines
- Ad vector, 523
  - cancer cell, 520
  - dendritic cell, 520–521
  - DNA cancer vaccines, 521–522
  - RNA vaccines, 522
  - viral vector-based cancer, 522–523
- Vaccinia virus, 541
- Vascular endothelial growth factor receptor 2 (VEGF-R2), 143
- Vascular endothelial growth factors (VEGFs)
  - cancer biomarker, 127–128
  - ovarian cancer, 206
- VeracYTE. *See* Afirma Gene Expression Classifier
- Veridex. *See* CellSearch system;
  - GeneSearch™ breast sentinel lymph node intraoperative assay
- Vermillion, 327
- Vesicular stomatitis virus (VSV), 541–542
- Viragen, 375–376
- Virus-mediated oncolysis, 536–537
  - adenoviruses, 538–540
    - advantages, 542
    - companies developing oncolytic viruses, 542–543
    - cytokine-induced killer cells, 537
    - drawbacks, 542
    - HSV, 540
    - measles viruses, 540–541
    - PET, 537–538
    - vaccinia virus, 541
    - vesicular stomatitis virus, 541–542
- Volatile organic compounds (VOCs)
  - breast cancer, 147
  - CRC, 175
  - exhaled breath, 196
- Volociximab, 376
- W**
- Warburg effect, 7
- Whole-genome sequencing (WGS), 33, 44, 771
- X**
- Xenon-enhanced MRI, 118
- xMAP technology, 204
- Y**
- Yale apoptosis assay, 775–776
- YKL-40, 198
- Yttrium-90, 380, 382
- Z**
- 19z1, 533, 716
- 14-3-3zeta positive expression, 136, 743
- Zevalin. *See* Ibritumomab tiuxetan
- Zinc oxide (ZnO) nanomaterials, 418